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Abstract 
Multiple myeloma is associated with a significant risk of venous thromboembolism (VTE), causing 
substantial levels of morbidity and mortality. The thrombogenicity of myeloma is multifactorial, with 
disease- and treatment-related factors playing important roles.  Immunomodulatory drugs (IMiDs) and 
high-dose dexamethasone, in particular, are known to enhance the thrombotic potential of myeloma. 
For this reason, assessment of the VTE risk has long been advocated prior to treatment initiation in 
patients with myeloma requiring IMiD-based regimens. However, despite routine use of 
thromboprophylaxis, these patients can still develop VTE and its sequelae. The optimum choice and 
dose of thromboprophylactic drug is not entirely clear, and with this, there is growing interest 
regarding use of the direct oral anticoagulants (DOACs) in this setting.  
In this review we discuss the pathogenesis of thrombosis in multiple myeloma, its relation to some of 
the commonly used chemotherapeutic regimens, current risk stratification and the evidence 
supporting the different anticoagulants used as thromboprophylaxis. We propose an amended risk 
stratification, and consider management of challenging patients including those with renal impairment 
and recurrent thrombosis. 
 
Introduction 
 
Risk of venous thromboembolism (VTE) is significantly increased in patients with cancer (4.3 fold 
increased incidence) (Blom, et al 2005), and VTE is the second commonest cause of death in these 
patients, other than the malignancy itself (Ambrus, et al 1975, Donati 1994, Khorana, et al 2007, 
Schoen, et al 2018). Amongst haematological malignancies, multiple myeloma confers an especially 
high risk with at least 10% of patients developing VTE during their disease history (Barlogie, et al 
1999, Eby 2009, Falanga and Marchetti 2009, Kristinsson, et al 2010). A recent review of nearly 5000 
myeloma patients showed VTE to be significantly associated with increased mortality at two and five 
years after diagnosis, independent of other known prognostic factors (Schoen, et al 2018).  Although 
VTE risk is highest with active myeloma, it also extends to some degree to those with monoclonal 
gammopathy of uncertain significance (MGUS). A large retrospective study of over 4 million US 
veterans found a threefold increased risk of VTE in MGUS cases, and a nine-fold increased risk in 
myeloma cases (Kristinsson, et al 2008). As VTE is associated with an increased mortality 
(Sanfilippo, et al 2014), appropriate identification of VTE risk factors and subsequent stratification of 
patients is of paramount importance in the optimal care of patients with myeloma.  
Our aim was to review the pathophysiology of thrombosis in myeloma, how this is affected by 
common anti-myeloma treatments, and the efficacy of the thromboprophylactic agents available. 
Finally, we propose practical algorithms for assessment of thrombotic risk, choice of prophylaxis, and 
management of VTE recurrence. MEDLINE, EMBASE, and NHS EVIDENCE were searched 
systematically for publications in English using the key words ‘thrombosis’, ‘anticoagulation’ and 
‘multiple myeloma’. References from relevant publications were also searched. Editorials, studies with 
<8 cases and letters were excluded. Conference abstracts have been included if deemed to be of 
particular relevance. 
 Pathogenesis of thrombosis in Myeloma 
Several disease-related, treatment-based and patient-related factors can lead to thrombosis in 
myeloma (Amrani 1990, Auwerda, et al 2007, Bellotti, et al 1989, Dong, et al 2018, Elice, et al 2006, 
Esmon 2001, Gado, et al 2000, Guo, et al 2018, Kotlin, et al 2008, Mechtcheriakova, et al 1999, 
O'Kane, et al 1994, Palumbo, et al 2004, Stirling, et al 1998, Thiagarajan, et al 2000, Yagci, et al 
2003, Yasin, et al 1999, Zangari, et al 2003). The effect of plasma cell neoplasms on thrombotic risk 
is paramount and the various ways they can promote clot formation is given in Table 1.  Risk of VTE 
is well documented to be increased during the active phase of disease, particularly during the first six 
months of treatment. This risk can be further augmented by certain therapeutic agents, in particular 
the immunomodulatory drugs, and especially in combination with high doses of corticosteroids and 
chemotherapy. 
 
Table 1. Thrombotic risk factors in plasma cell neoplasms 
Disease-related Treatment-related Patient-related 
Immunoglobulin dependent 
• Hyperviscosity eg. serum 
viscosity >4 cp (serum IgG 
usually40 g/l, or IgA 60 
g/l)*(Zangari, et al 2003) 
• Defective fibrin polymerisation 
and fibrinolysis (Kotlin, et al 
2008, O'Kane, et al 1994, 
Thiagarajan, et al 2000, Yagci, 
et al 2003) 
• Lupus anticoagulant activity 
(LAC) of the paraprotein, 
antibodies against Protein S 
and C, acquired Activated 
Protein C (APC) resistance 
(Bellotti, et al 1989, Yasin, et 
al 1999) 
Immunoglobulin independent 
• Elevated PAI-1 (plasminogen 
activator inhibitor-1)  
• Increased proinflammatory 
cytokines IL-6 and VEGF 
(Amrani 1990, Gado, et al 
2000, Mechtcheriakova, et al 
 
Drugs 
• Thalidomide/Lenalidomide 
• Dexamethasone 
• Multiagent chemotherapy 
• Proteasome inhibitors- 
bortezomib exerts a protective 
effect, carfilzomib is a risk factor 
for VTE 
• Erythropoietin stimulating 
agents 
• Indwelling central catheters 
(Palumbo, et al 2008) 
 
 
 
• Fractures and other causes 
of immobility 
• Severe infections 
• Elevated body mass index 
• Comorbidities eg. cardiac 
disease, chronic renal 
failure, diabetes mellitus, 
inflammatory bowel 
disease, autoimmune 
disease 
• Surgery, anaesthesia, 
trauma 
• History of VTE or inherited 
thrombophilias (not 
myeloma-specific) 
(Palumbo, et al 2008) 
 
 
*IgM myeloma is uncommon. Hyperviscosity predisposing to increased risk of thrombosis is more 
likely to occur if serum IgM is >30g/l. 
 
Dexamethasone 
Corticosteroids have been associated with VTE in different diseases including myeloma 
(Johannesdottir, et al 2013). High doses of dexamethasone have been shown to stimulate increased 
expression of tissue factor (TF), cellular adhesion molecules (ICAM-1, VCAM-1 and E-selectin) and 
von Willebrand factor (VWF), and decreased expression of thrombomodulin (TM) and plasminogen 
activator inhibitor-1 (PAI-1) by HUVEC cells in vitro (Kerachian, et al 2009), with similar 
antifibrinolytic effects seen in rats (van Giezen and Jansen 1992). Dexamethasone may act 
indirectly, by sensitizing cells to cytokine stimulation eg. tumour necrosis factor alpha (TNF-), but 
there is limited definitive data available to confirm its mode of action. Indeed, at low doses, 
glucocorticoids may even have a protective effect against inflammation and thrombosis. In the context 
of orthopaedic surgery, administration of hydrocortisone pre-operatively was associated with a 
significant reduction in markers of thrombin generation, and a non-significant increase in fibrinolysis 
markers (McLawhorn, et al 2015).  
What is known however, is that clinically, the addition of steroids, particularly at higher doses, is 
associated with a significant elevation in thrombosis risk. Rajkumar et al. reported a comparison 
between lenalidomide with high- or low-dose dexamethasone. In this study, high-dose was referred to 
as 40 mg dexamethasone on days 1-4, 9-12 and 17-20 of a 28 day cycle, versus low-dose where 
40mg of dexamethasone was administered once weekly. The total dose of dexamethasone received 
in the ‘high-dose’ group was 480mg/month, in line with the IMWG’s later definition of ‘high-dose’ 
1999, Stirling, et al 1998) 
• Increased endothelial TF 
(tissue factor) expression 
(Dong, et al 2018) 
• Elevated FVIII, VWF and 
fibrinogen levels (Auwerda, et 
al 2007, Stirling, et al 1998) 
• Increased cell surface 
phosphatidylserine expression 
(Dong, et al 2018, Guo, et al 
2018) 
• Acquired APC resistance due 
to reduced levels of 
thrombomodulin (TM) (Elice, et 
al 2006, Esmon 2001) 
 
glucocorticoids (Palumbo, et al 2008). In the initial part of the study, VTE prophylaxis was 
recommended but not mandated. Of the first 266 enrolled patients, 18.2% developed VTE in the high-
dose group and 3.7% in the low-dose group, after which thromboprophylaxis became mandatory 
(Rajkumar and Blood 2006). At one year from study initiation, the VTE rate in the high-dose group 
was over double that of the low-dose group (26% vs 12%), providing substantial supportive evidence 
for the thrombogenic potential of high-dose dexamethasone (Rajkumar, et al 2010). 
Immunomodulatory agents 
 
Thalidomide is the first in the class of immunomodulatory drug (IMiD) used for myeloma treatment. Its 
mode of action is multifactorial, affecting angiogenesis, adhesion of myeloma plasma cells, and 
regulation of the immune system (Palumbo and Palladino 2012). VTE can be associated with single-
agent thalidomide use, but is seen more often when thalidomide is combined with glucocorticoids, and 
is a frequent complication of treatment with high-dose dexamethasone or combination chemotherapy 
(Barlogie, et al 2001, Bennett, et al 2002, Li, et al 2017, Rajkumar, et al 2002, Tosi, et al 2002, Weber 
2002). Rates of VTE seen with thalidomide with the addition of dexamethasone range from 2-17% 
(Cavo, et al 2004, Dimopoulos, et al 2001, Rajkumar, et al 2006) while with combination 
chemotherapy, rates of 10-58% have been reported (Barlogie, et al 2006, Baz, et al 2005, Schutt, et 
al 2005, Zangari, et al 2002, Zervas, et al 2004).The highest incidence (58%) was reported by Baz et 
al. in their trial evaluating the use of thalidomide in association with doxorubicin, vincristine and 
dexamethasone (Baz, et al 2005). Thrombosis rates are higher in newly diagnosed patients than 
those with relapsed/refractory disease (2-15% vs 3-34%) although the exact reasons for this 
difference is unclear (Palumbo, et al 2008). The incidence is maximal during the first three months of 
treatment and decreases after about 12 months (Zangari, et al 2004a, Zangari, et al 2002), possibly 
due to release of prothrombotic factors from apoptotic myeloma cells when burden of disease is at its 
highest (Zangari, et al 2003). In vitro studies have shown that application of thalidomide to endothelial 
cells damaged by doxorubicin exposure leads to altered Protease activated receptor-1 (PAR-1) 
expression, indicating endothelial dysfunction (Baz, et al 2005). This may in part explain the extremely 
high rate of thrombosis seen by Baz et al. Association studies have also suggested a link between 
IMiDs and increased endothelial TF expression (Li, et al 2017). A transient reduction in levels of 
soluble TM was reported during the first month of therapy in a group of 13 relapsed refractory 
patients, one of whom developed VTE (Corso, et al 2004). Interestingly, IMiDs themselves have not 
been shown to cause endothelial damage (Streetly, et al 2005). The thrombogenicity of thalidomide 
may therefore be potentiated by endothelial damage from combination chemotherapy, and 
dexamethasone-induced sensitization of cells to cytokine stimulation, which is known to be 
upregulated by IMiDs. 
 
Lenalidomide is a second-generation immunomodulatory agent with increased in vitro efficacy 
compared with thalidomide, and less toxicity in data pooled from different trials (no head-to-head 
comparison of thalidomide and lenalidomide exists in the literature). Like thalidomide, single agent 
lenalidomide has a modest thrombogenic potential (reported incidence 4%) (Richardson, et al 2009) 
which is enhanced by the addition of glucocorticoids, particularly high-dose dexamethasone (VTE 
26% versus 12% high ie. 480mg/month versus low-dose dexamethasone) (Dimopoulos, et al 2007, 
Rajkumar, et al 2010, Weber, et al 2007, Zonder, et al 2005), and combination chemotherapy (14% 
when used with cyclophosphamide and 9% with doxorubicin) (Baz, et al 2006, Knop, et al 2006, 
Morgan, et al 2007).VTE rates are again higher in newly diagnosed patients. A meta-analysis of 125 
patients enrolled in three clinical trials stratified the patients into high and low-VTE risk groups based 
on the concomitant dose of dexamethasone administered (40 mg weekly, or 40mg on 12 days/month, 
total 480mg/month). Most of the patients (110) received thromboprophylaxis, which in the majority 
was 325 mg aspirin once daily. The VTE rate was 12% for the high-dose dexamethasone group, 6% 
in the low-dose group, 7% in those on aspirin and 13% in those not receiving thromboprophylaxis. 
7/10 VTE episodes occurred during the initial six months of therapy in keeping with the known 
increased thrombogenic potential associated with high disease burden (Menon, et al 2008). 
Consistent with these results, the Greek Myeloma Study Group analysed 212 relapsed refractory 
patients treated with lenalidomide and low-dose dexamethasone outside of clinical trials, and reported 
a similar VTE incidence of 5.7% overall (Katodritou, et al 2014). 
 
There is less evidence again regarding the third-generation immunomodulatory agent, pomalidomide. 
A small phase I study of 24 relapsed refractory patients receiving single agent pomalidomide reported 
VTE in 17% without thromboprophylaxis (Schey, et al 2004). Subsequent studies have incorporated 
varying doses of thromboprophylaxis into treatment regimens. Of 60 relapsed-refractory patients 
receiving pomalidomide with low-dose weekly dexamethasone, only one thromboembolic event was 
reported (1.6%). All patients were thromboprophylaxed with a high dose of aspirin (325mg), 
therapeutic dose LMWH or warfarin with a target INR of 2-3 (of note, none of these 
thromboprophylaxis strategies would be routinely chosen in current clinical practice) (Lacy, et al 
2009). A recent study of pomalidomide in combination with low-dose dexamethasone and bortezomib 
in 50 patients reported a higher VTE rate of 10%, despite using the high doses of thromboprophylactic 
agents detailed in the previous study (Paludo, et al 2017).  
 
 
Proteasome inhibitors 
 
The first in-class proteasome inhibitor is bortezomib which reversibly inhibits the 20S subunit of the 
26S proteasome. Downstream suppression of nuclear factor B(NF-B) mediated transcription factor 
production results in enhanced expression of the natural anticoagulant endothelial TM via induction of 
Kruppel-like transcription factors. Bortezomib can also prevent TM downregulation by inflammatory 
cytokines (Hiroi, et al 2009, Lonial, et al 2008, Nayak, et al 2014). Data relating to bortezomib use 
suggests a far lower, or possibly even absent, thrombogenic potential. Addition of bortezomib to 
melphalan-prednisolone in the phase 3 VISTA trial was not associated with increased VTE rates (San 
Miguel, et al 2008). The APEX trial of single-agent bortezomib versus high-dose dexamethasone in 
relapsed patients reported differential VTE rates of 0.6% for bortezomib versus 2.7% in the 
dexamethasone arm (Lonial, et al 2008). Addition of bortezomib to the DT-PACE regimen 
(dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide) was 
associated with a significant reduction in thrombotic episodes, from 10% to 0% (Zangari, et al 2004b). 
In the frontline setting, Zangari et al. reviewed phase 3 trials of bortezomib and/or immunomodulatory 
agent-based therapy. Regimens including bortezomib had overall VTE rates of 5% whereas IMiD-
based treatment without bortezomib was associated with higher rates, further corroborating the low 
thrombogenicity associated with bortezomib (Zangari, et al 2011).  
 
A small study involving 10 patients with relapsed multiple myeloma described in vivo effects of 
bortezomib on routine coagulation tests and impairment of platelet function. Platelet aggregation with 
different agonists was decreased after bortezomib infusion with statistically significant results with 
ADP on days one, (20% decrease, p=0.033) and four (29% decrease, p=0.009). Similar results were 
also obtained with epinephrine-induced platelet aggregation and ristocetin-induced agglutination. 
Expression level of the platelet surface marker, P-selectin, which has roles in adhesion and 
thrombosis, was also decreased after bortezomib treatment (Zangari, et al 2008). This anti-platelet 
effect and alteration in adhesion properties may explain the low VTE rates seen with proteasome 
inhibition.  
 
There is less available data on the second-generation proteasome inhibitor carfilzomib, which unlike 
bortezomib, causes irreversible inhibition of the 26S proteasome. The phase 3 study ASPIRE 
compared the triplet of carfilzomib, lenalidomide and dexamethasone, with lenalidomide and 
dexamethasone.  VTE incidence during the first year was 13% versus 6% against the carfilzomib arm 
(Stewart, et al 2015), with significant rates of carfilzomib-related cardiovascular disease 
(hypertension, arrhythmias, myocardial infarction, and congestive cardiac failure) noted in this and 
other studies. These effects, suspected to be a reflection of endothelial toxicity possibly related to the 
irreversible 26S proteasome inhibition, appear to be specific to carfilzomib and are not seen with 
bortezomib.   
 
Prophylaxis – risk stratification 
Assessment of VTE risk in myeloma has been advocated for many years (Palumbo, et al 2008), the 
mainstay of which requires a thorough clinical history, with close attention being paid to the features 
described in Table 1. Re-assessment is suggested at diagnosis, relapse, or when otherwise clinically 
indicated eg. if the patient develops VTE, or at instigation of a new non myeloma-related therapy with 
increased thrombogenic potential. 
 
Optimal choice of pharmacological prophylaxis and appropriate patient VTE risk-stratification in 
patients with myeloma requires ongoing attention. Recent results from the large, phase 3 Myeloma XI 
trial highlight this fact. The updated analysis showed an overall VTE rate of 12.4%, 11.1% of which 
was during the first 6 months of therapy, with no differences seen between the thalidomide and 
lenalidomide-containing regimens. By far the majority of patients (87.6%) were on some type of 
thromboprophylaxis prior to VTE with only 12.4% of patients not receiving thromboprophylaxis. 
However, the types and doses of thromboprophyaxis were variable and not accounted for by the 
preceding VTE risk assessment. Over 10% were on therapeutic dose LMWH prior to their thrombotic 
event, further emphasising the strong prothrombotic potential of selected patients (Bradbury 2017, C. 
A. Bradbury 2018). 
 
In 2008, The International Myeloma Working Group recommended a VTE risk assessment be 
performed in all multiple myeloma patients treated with thalidomide or lenalidomide.They suggested 
aspirin prophylaxis (dose 81-325mg once daily) for those with no or one risk factor, LMWH or 
therapeutic dose warfarin if two or more risk factors are present, and the same for those receiving 
high-dose dexamethasone, doxorubicin or multi-agent chemotherapy irrespective of preceding risk 
factors (Palumbo, et al 2008). The recommendations were provided with the caveat that they were 
based on the limited available data alongside expert opinion, and do not provide a definitive model for 
this issue. The British Society of Haematology guidelines on the supportive care of multiple myeloma, 
2011, concur with this advice (Snowden, et al 2011), as do the 2016 National Institute of Clinical 
Excellence (NICE) guidelines, once again acknowledging the relative lack of rigorous evidence on the 
topic (NICE Clinical guidelines 2016). However, the most recent guidance from NICE in 2018, merely 
suggests that either aspirin or prophylactic dose LMWH may be considered equivalent for myeloma 
patients receiving chemotherapy with IMiDs and a corticosteroid (guidelines 2018). 
 
Although risk assessment tools are available, there is evidence to suggest that clinicians are often 
stratifying patients according to personal perception of strength of certain risk factors, for example 
placing more weight on a family history than treatment with high-dose dexamethasone. The MELISSE 
study was a large, multicentric, observational study which sought to evaluate VTE incidence, risk 
assessment and prophylaxis chosen in real-life practice in France. Of 513 patients on lenalidomide- or 
thalidomide-based regimens, 47% were deemed to be at low VTE risk, 39% intermediate and 14% 
high. Patients were managed with either aspirin, LMWH or VKA. At 12 months follow-up, VTE rates 
were 7% for aspirin, 3% LMWH and 0% in the VKA-treated group with no statistical significance 
identified. However, risk stratification was not standardised. 47% of patients were thought to be low 
risk, however only 15% had fewer than 3 VTE risk factors. Choice of prophylaxis was also not 
standardised and did not follow current international recommendations (Palumbo, et al 2008), with 
19% of high-risk individuals receiving low-dose aspirin, and LMWH or VKA only prescribed for 40% of 
intermediate- and high-risk patients. A lack of consensus and clarity appeared evident with respect to 
both risk stratification of patients and subsequent choice of thromboprophylaxis (Chalayer, et al 
2016b, Leleu, et al 2013). 
 
Attempts to improve VTE risk stratifications have been made and various groups are investigating 
markers of thrombosis that could be incorporated into practical, validated risk assessment tools. 
Elevated levels of soluble p-selectin, an adhesion protein which mediates interactions between 
platelets, leucocytes and cancer cells, have been shown to be associated with an increased risk of 
VTE, and incorporated into the Vienna risk prediction model (Ay, et al 2008). Other markers under 
investigation include D-dimers, microparticles and tissue factor, which was shown to be associated 
with recurrence of VTE in the CATCH trial (Khorana, et al 2017).Very recently, a group analysed 
conventional clinical myeloma risk factors such as dexamethasone use, thalidomide, previous VTE, 
central venous catheter in situ, and obesity, and developed a new risk model (the myeloma clot score, 
MCS), which they validated (Kristen Marie Sanfilippo 2018). 
 
Point of care tests of global hemostasis may play a future role in identifying patients with 
prothrombotic haemostatic profiles, and perhaps in highlighting those with features of resistance to 
heparin or other anticoagulation (see recurrent thrombosis section). Given their increasing importance 
in other areas such as management of major haemorrhage, it is likely they may be of use in this field 
also, however more research is required.  
 
 
Prophylaxis – choice of agent 
 
Aspirin versus LMWH 
 
The IMWG have advised the use of aspirin in low VTE risk patients receiving IMiD-based regimens, 
concluding from the available evidence that it is of clinical utility in this subgroup (Palumbo, et al 
2008). Due to its oral route and lack of monitoring, it is an appealing option for patients, however most 
of the current evidence is not based on randomized trials, and published results do not uniformly 
show benefit. A study of patients receiving combination chemotherapy with thalidomide, pegylated 
doxorubicin, vincristine and dexamethasone without pharmacological thromboprophylaxis yielded a 
VTE incidence of 58% which was reduced to 18% in subsequent patients by the addition of aspirin 
81mg daily (Baz, et al 2005). A small study of 34 patients receiving lenalidomide, dexamethasone and 
aspirin reported a 3% VTE rate (Rajkumar, et al 2005). A subsequent, larger, randomized study of 
lenalidomide with high or low dose dexamethasone found the addition of low-dose aspirin reduced 
VTE rates from 23% to 14% for high-dose dexamethasone patients and from 14% to 5% for low-dose 
patients (Rajkumar, et al 2006). A study of melphalan, prednisolone and lenalidomide with aspirin 
100mg reported a 5% VTE rate (Palumbo, et al 2007), and another of lenalidomide, doxorubicin and 
dexamethasone with 81mg aspirin reported a 9% rate (Baz, et al 2006).  
More recently, 342 patients treated with lenalidomide-based induction and consolidation therapy 
(lenalidomide and low-dose dexamethasone induction, and melphalan-prednisolone-lenalidomide 
consolidation) were randomized between aspirin 100mg daily and enoxaparin 40mg daily. This 
prospective, open-label, randomized sub-study of a phase 3 trial showed that during the first 6 months 
post-randomisation, VTE incidence was 2.27% in the aspirin group and 1.20% in the LMWH group, 
with an absolute difference of 1.07% (95% confidence interval, -1.69-3.83; P = .452) in favour of 
enoxaparin. Importantly, high-risk patients were excluded including those with recent orthopaedic 
surgery, vertebroplasty, immobilisation, thrombophilia, known ischaemic heart disease or previous 
atrial fibrillation, and none of the cohort had a past history of VTE (Larocca, et al 2012).  Another 
larger randomised trial of 667 patients receiving thalidomide-based first-line myeloma therapy 
compared aspirin 100mg, fixed low-dose warfarin 1.25mg and enoxaparin 40mg. Reported rates of 
serious thromboembolic events, acute cardiovascular events or sudden death during the first 6 
months were 6.4% for aspirin, 8.2% for warfarin and 5.0% for LMWH. Three major and 10 minor 
bleeding episodes were recorded. High risk patients were excluded in this trial. The authors 
concluded from their data that aspirin was an effective prophylactic agent in low-risk patients, 
although there was no placebo arm for comparison. Of note, in this trial, the risk of VTE was 1.38 
times greater in patients treated with thalidomide without bortezomib (Palumbo, et al 2011). 
 
In terms of lenalidomide, a systematic review of over 1126 patients found overall VTE occurrence 
rates of 10.7% in patients receiving aspirin prophylaxis versus 1.4% for those on LMWH. The highest 
risk was in patients taking lenalidomide with high-dose steroids (26.6%), compared with low-dose 
dexamethasone (10.3%) or melphalan, lenalidomide, prednisolone (MPR) (4.1%). They concluded 
that aspirin may be insufficient for regimens incorporating high doses of dexamethasone but may be a 
safe option for lower risk treatments such as MPR (Al-Ani, et al 2016). In contrast to these findings, a 
large retrospective cohort study of 4892 multiple myeloma patients in whom 586 developed VTE did 
not find evidence that aspirin reduced the risk of VTE, after adjusting for risk factors including IMiD 
use and past history of VTE. They suggested that aspirin may be insufficient for patients on 
immunomodulatory agent-based treatments and also those with a personal history of VTE (Sanfilippo, 
et al 2017).  
 
From an economic standpoint, the limited cost associated with low-dose aspirin is advantageous. 
Chalayer E et al. performed a cost-effectiveness analysis of LMWH versus aspirin in newly diagnosed 
multiple myeloma patients, based on Palumbo et al.’s work (Palumbo, et al 2011). In their model, 
aspirin use was associated with a higher frequency of VTE, stroke, major bleeding, but reduced 
incidence of acute myocardial infarction, and due to the difference in route of administration, a slightly 
higher quality-adjusted life years (QALY) than LMWH (0.300 versus 0.299). Over 6 months of 
treatment, using aspirin in place of LMWH was calculated to save 1245 Euros on average per patient, 
with a slight improvement in quality of life. These results of course do not apply to patients who 
develop VTE with its associated complications, and no assessment of VTE risk was made in this 
model (Chalayer, et al 2016a). 
 
Data supports low-dose aspirin as a reasonable option for patients on IMiD-containing regimens who 
are otherwise at low-risk of thromboembolic complications, although the number of patients in this 
category is likely to be small. Given the conflicting results available, we would generally recommend 
offering prophylactic LMWH to all patients receiving initial Multiple Myeloma treatment with an IMiD in 
combination with corticosteroid or chemotherapy, at least during the initial 6 months of treatment 
when risk of thrombosis is at its highest. Aspirin could be considered beyond 6 months in the absence 
of additional significant patient related VTE risk factors. However, these recommendations are not 
based on robust evidence or any formal guideline. Prophylactic dose LMWH confers the greatest 
protection out of the conventional agents available, and is therefore the drug of choice for ‘high-risk’ 
individuals. There is some evidence that it may be inadequate for particularly high-risk patients who 
may benefit from more intensive VTE prophylaxis. However, there is a lack of evidence that a higher 
dose of anticoagulation is effective and safe, and risk of thrombosis and haemorrhage must be 
balanced if intensification of anticoagulation is to be considered.  
 
 
Warfarin 
 
The little data available on warfarin as thromboprophylaxis suggests that at therapeutic doses aiming 
for an INR between 2 and 3 it isn’t superior to prophylactic dose LMWH (Palumbo, et al 2011), and 
that at low fixed doses eg.1-1.25mg daily, it has poor efficacy. One study of thalidomide, 
dexamethasone and low dose warfarin saw a VTE incidence of 25% (Weber, et al 2003), and another 
of thalidomide, dexamethasone and chemotherapy reported a rate of 31% with fixed dose warfarin 
prophylaxis versus 15% with 40mg enoxaparin (Zangari, et al 2004a). Warfarin also has the potential 
for drug interactions and of course the need for frequent blood tests. Fluctuations in the INR due to 
issues with absorption (from vomiting and other GI issues), drug interactions, low albumin, systemic 
illnesses and interruptions for procedures can make warfarin a less attractive option. An additional 
practical issue to consider is the fluctuating thrombocytopenia which often develops in patients on 
proteasome inhibitors. The increased bleeding risk associated with a platelet count <50 x 109/l also 
needs consideration in these patients.  
 
The role of DOACs 
 
The direct oral anticoagulants (DOAC), either inhibitors of factor Xa (apixaban, rivaroxaban, 
edoxaban, betrixaban) or IIa (dabigatran), are an attractive option for VTE prophylaxis in myeloma, 
requiring no monitoring at routine doses, and sparing patients from daily subcutaneous injections. 
None of the DOACs are currently licensed for this use. A meta-analysis of trials comparing DOACs to 
VKAs for treatment of acute VTE in over 27,000 patients, without a specific diagnosis of myeloma, 
reported overall lower rates of VTE recurrence, major bleeding including fatal bleeds and intracranial 
haemorrhage, and clinically relevant non-major bleeds. Subgroup analysis of participants with cancer 
reported a hazard ratio of 0.57 for VTE recurrence in favour of the DOACs (van Es, et al 2014). There 
is also evidence for the use of DOACs in the setting of secondary VTE prevention, at reduced, 
prophylactic doses. This is provided by EINSTEIN CHOICE, where low dose rivaroxaban (10mg) was 
superior to aspirin (100mg) at prevention of VTE recurrence with equally low rates of bleeding (Weitz, 
et al 2017), and by AMPLIFY EXT which found 2.5mg twice daily apixaban to be as effective as 5mg 
twice daily, without increased bleeding compared with placebo (Agnelli, et al 2013).    
 
Two recent trials have evaluated use of a DOAC in cancer patients for the treatment of VTE, one 
comparing edoxaban to dalteparin and the other rivaroxaban to dalteparin (Hokusai and SELECT-D 
respectively). Both studies obtained similar results. The HOKUSAI trial reported a 12-month VTE 
recurrence rate favouring edoxaban (7.9% versus 11.3), but with a slight increase in major bleeding 
(6.9% versus 4%). Similarly, the SELECT-D saw a reduction in 6-month VTE recurrence with 
rivaroxaban (4% versus 11%), a slight increase in major bleeding (6% versus 4%) and a significant 
increase in clinically significant non-major bleeding events in the DOAC arm (13% versus 4%). A 
significant proportion of bleeds were upper gastrointestinal in source, and more common amongst 
patients with gastric tract malignancies (Raskob, et al 2018, Young, et al 2018), which would be of 
limited relevance in the setting of myeloma. These studies did include some myeloma patients, 
however numbers were very small eg. one patient in the DOAC arm in SELECT-D. They also did not 
address the issue of VTE prophylaxis in cancer.  
 
Data regarding prophylactic use of the DOACs in the cancer setting is presently sparser, and based 
mainly on small case series and case reports, but with promising results seen. A retrospective review 
of patients on IMiD-based regimens receiving therapeutic dose warfarin (16 patients) or therapeutic or 
prophylactic doses of dabigatran, rivaroxaban or apixaban (21 patients) as thromboprophylaxis 
reported four non-major bleeds in the DOAC group versus a total of six bleeds in the warfarin group, 
two of which were major, and no VTE events in either group (Man, et al 2017). A larger review of 70 
patients receiving apixaban 2.5mg BD during front-line therapy with IMiD-containing regimens 
reported no episodes of VTE within the first 6 months, one ischaemic stroke, one NSTEMI in a patient 
with known ischaemic heart disease and one episode of major bleeding in a patient with concomitant 
severe thrombocytopenia. VTE risk assessment scores for the cohort are not available, however two 
patients had previous PE, two had a history of stroke or transient ischaemic attack and three had 
documented prior MI (Storrar, et al 2018). A prospective randomized controlled trial of apixaban 
2.5mg BD versus placebo in myeloma patients on IMiD-based therapy, is ongoing (NCT02958969), 
and a large, multi-centre study comparing DOACs, LMWH and warfarin in VTE prophylaxis in cancer 
patients (CANVAS trial, NCT02744092) is also in recruitment.  
Lack of routine monitoring at prophylactic doses is an attractive quality for patients, however may be 
an issue in patients where GI absorption is altered (eg. chemotherapy-induced vomiting and 
diarrhoea), when drug clearance is reduced in renal failure, or when drug interactions with 
chemotherapeutic agents and supportive treatments are unknown. Drug level monitoring may be a 
solution to these problems but isn’t currently widely available and there is no evidence to guide 
thromboprophylaxis drug level targets for this indication, or dose alterations based on drug levels. In 
addition to this, in comparison with solid cancers, bleeding risk in myeloma is likely to be higher due to 
older age of the patients, co-existing thrombocytopenia and higher prevalence of renal dysfunction. 
Currently, a reversal agent is only available for dabigatran but not yet for rivaroxaban, apixaban or 
edoxaban. Bleeding episodes related to the direct anti-Xa inhibitors require treatment with pro-
haemostatic products (eg; prothrombin complex concentrate).  
The problems which may arise with DOAC use is presented in the table 2.  
 Table 2: Practical issues with DOAC use in patients with myeloma 
 
• Dosing –. We lack definitive evidence that prophylactic doses of DOACs are adequate in all 
patients who require thromboprophylaxis with myeloma. This is especially of concern since it 
is known that prophylactic doses of low molecular weight heparin do not prevent thrombosis 
in very high-risk patients. Escalated doses of DOACs are likely to reduce VTE recurrence 
rates, but possibly at the expense of increased haemorrhagic complications. Well-designed 
RCTs are needed to clarify this issue.  
• Drug interactions –concomitant administration of DOACs with myeloma-specific treatment, 
and supportive medications (eg. azole antifungals etc.) is yet to be evaluated  
• Extremes of body weight – Steroid use may cause weight gain in myeloma patients while 
cachexia may be an issue in some others. There is insufficient data for DOACs in extremes of 
body weight. 
• Renal impairment – optimal dosing strategies depending upon severity of renal impairment 
are not yet known. The various DOACs have different licenses based upon creatinine 
clearance or eGFR threshold, and levels are further affected by hypoalbuminaemia. This is 
discussed further in the renal impairment section. 
 
 
 
Table 3: Primary experimental trials using IMiDs in multiple myeloma (meta-analyses 
excluded) 
Study- reference Regimen and patients Exclusions Thromboprophylaxis VTE rate 
Thalidomide  
(Barlogie, et al 
2001) 
 
 
(Tosi, et al 2002) 
 
 
 
 
Thalidomide-
dexamethasone 
(Cavo, et al 2004) 
 
 
 
 
 
(Rajkumar and 
Blood 2006) 
 
 
 
 
 
(Rajkumar, et al 
2002) 
 
169 relapsed/refractory 
patients- single-agent 
thalidomide 
 
65 relapsed/refractory 
patients- single agent 
thalidomide (max 800mg 
daily) 
 
 
 
71 newly diagnosed 
patients, thalidomide with 
high-dose dexamethasone 
prior to ASCT  
 
 
207 patients with newly 
diagnosed myeloma 
randomized to high dose 
dexamethasone +/- 
thalidomide 
 
 
50 patients with newly 
diagnosed myeloma- 
 
Renal/liver 
impairment NOT 
excluded 
 
None stated 
 
 
 
 
 
 
>65 yrs, history of 
thrombosis 
 
 
 
 
Severe renal 
impairment,  liver 
impairment, 
cytopenias, or 
past/current 
thrombosis 
 
Severe cytopenias, 
poor performance 
 
Not described 
 
 
 
None  
 
 
 
 
 
 
1st 19 patients- no 
thromboprophylaxis, 
remaining 52- 
1.25mg prophylactic 
warfarin 
 
None 
 
 
 
 
 
 
None 
 
 
<2% 
 
 
 
1.5% 
 
 
 
 
 
 
26% without 
warfarin, 13% 
with warfarin 
 
 
 
17% in the 
thalidomide 
arm vs. 3% 
without  
 
 
 
Single agent 
arm 4%, 
 
 
 
 
 
(Weber, et al 
2003) 
 
 
 
 
 
 
 
 
 
Thalidomide 
combination 
therapy 
(Barlogie, et al 
2006) 
 
 
 
 
(Baz, et al 2005) 
 
 
 
 
 
 
 
(Palumbo, et al 
2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Schutt, et al 
2005) 
 
 
 
(Zangari, et al 
2004) 
 
 
 
 
 
 
 
 
 
 
(Zangari, et al 
thalidomide with 
dexamethasone at 
alternating high and low 
doses 
 
28 newly diagnosed 
asymptomatic myeloma 
patents- single agent 
thalidomide (max dose 
600mg), 40 patients- 
thalidomide with high-dose 
dexamethasone 
 
 
 
 
 
 
 
Newly diagnosed MM 
randomized to melphalan-
ASCT+/- thalidomide  
 
 
 
105 Newly diagnosed or 
relapsed patients- 
thalidomide, peglylated 
doxorubicin and vincristine  
 
 
 
 
667 patients treated with 
thalidomide-containing 
regimen: if <65 yrs, 
bortezomib, thalidomide, 
and dexamethasone, or 
thalidomide and 
dexamethasone with ASCT, 
if >65 yrs, melphalan, 
prednisolone, and 
thalidomide with 
maintenance, or 
bortezomib, melphalan, 
thalidomide and 
prednisolone without 
maintenance  
 
31 patients received 
thalidomide 400mg with 
vincristine, epirubicin and 
dexamethasone +/- ASCT 
 
Comparison between 98 
patients receiving DT-PACE 
and 68 receiving VDT-
PACE in the UARK 2001-12 
and 2003-33 trials 
respectively (VDT-PACE = 
velcade, dexamethasone, 
thalidomide, doxorubicin, 
cisplatin, Adriamycin, 
cyclophosphamide and 
etoposide) 
 
192 relapsed/refractory 
status 
 
 
 
 
Newly diagnosed 
patients. those with 
CRAB criteria were 
excluded 
 
 
 
 
 
 
 
 
 
 
Adequate 
performance 
status, renal failure 
not excluded 
 
 
Life-expectancy <3 
months, severely 
deranged liver 
function, impaired 
LV function  
 
 
 
Previous venous or 
arterial thrombosis 
or high risk of 
bleeding  
 
 
 
 
 
 
 
 
 
 
 
 
None stated 
 
 
 
 
None stated 
 
 
 
 
 
 
 
 
 
 
 
None stated 
 
 
 
 
 
None given in single-
agent arm, in 
combination arm, 1st 
24 patients received 
1mg OD coumadin, 
remaining 16 
received treatment 
dose LMWH or 
coumadin 
 
 
 
 
 
1st 162 patients did 
not receive 
thromboprophylaxis, 
remaining 163- 
prophylactic LMWH 
 
Aspirin 81mg OD 
PO, from the start of 
treatment, after 1 
cycle or not at all 
 
 
 
 
Aspirin 100mg OD 
PO, warfarin 1.25mg 
OD PO, or 
enoxaparin 40mg 
OD s/c 
 
 
 
 
 
 
 
 
 
 
 
Not specified  
 
 
 
 
Not specified 
 
 
 
 
 
 
 
 
 
 
 
Not specified 
combination 
15% 
 
 
 
34% vs 18% 
with or 
without 
thalidomide  
 
 
 
 
 
 
 
 
 
 
without 
LMWH, 24% 
vs 15% with 
LMWH 
 
 
VTE-19% 
(aspirin from 
the start), 
15% (from 
cycle 2) and 
58% (no 
aspirin) 
 
VTE rates (at 
6 months) 
6.4% for 
aspirin, 5% 
for LMWH 
and 8.2% for 
warfarin  
 
 
 
 
 
 
 
 
 
26% 
 
 
 
 
10% in DT-
PACE trial vs. 
0% for VDT-
PACE 
 
 
 
 
 
 
 
 
DVT occurred 
2002) 
 
 
 
 
 
(Zervas, et al 
2004) 
patients received DT-PACE 
and 40 received DCEP-T 
(same regime as DT-PACE 
without doxorubicin) 
 
 
39 newly diagnosed patients 
received thalidomide 
(200mg), vincristine, 
liposomal doxorubicin and 
dexamethasone  
 
 
 
 
 
 
None stated 
 
 
 
 
 
 
Not specified 
 
 
in 16.5% in 
the DT-PACE 
arm vs. 2.5% 
in the DCEP-
T arm  
 
DVTs in 10% 
Lenalidomide 
(Richardson, et al 
2009) 
 
 
 
 
 
Lenalidomide-
dexamethasone 
(Zonder, et al 
2005) 
 
 
 
 
 
(Weber, et al 
2007) 
 
 
 
 
 
(Dimopoulos, et al 
2007)  
 
 
 
 
 
(Rajkumar, et al 
2005) 
 
 
 
(Rajkumar, et al 
2010) 
 
 
 
 
 
 
Lenalidomide 
combination 
therapy 
(Baz, et al 2006) 
 
 
 
 
 
 
 
 
 
222 relapsed refractory 
patients received 
lenalidomide 30mg days 1-
21 
 
 
 
 
 
12 newly diagnosed patients 
received 25mg lenalidomide 
with high-dose 
dexamethasone, and 9 
received dexamethasone 
with placebo 
 
177 relapsed refractory 
patients received 
lenalidomide 25mg days 1-
21 with high dose 
dexamethasone, versus 176 
patients on a placebo arm 
 
351 Relapsed refractory 
patients received 
lenalidomide days 21 days 
per 28 day cycle and high-
dose dexamethasone, or 
placebo/dexamethasone 
 
34 newly diagnosed patients 
received lenalidomide 25mg 
days 1-21 and high dose 
dexamethasone 
 
445 newly diagnosed 
patients were randomized to 
lenalidomide 25mg days 1-
21 with either high or low 
dose dexamethasone +/- 
ASCT 
 
 
 
 
 
62 Newly diagnosed or 
relapsed patients receiving 
lenalidomide, peglylated 
doxorubicin and vincristine 
 
 
 
 
 
 
Non-myeloma 
related severe 
cytopenias, severe 
renal impairment, 
liver enzymes >3 
times ULN 
 
 
 
None stated 
 
 
 
 
 
 
Non-myeloma 
related severe 
cytopenias, severe 
renal impairment, 
liver enzymes >3 
times ULN 
 
Non-myeloma 
related severe 
cytopenias, Liver 
enzymes >2 times 
ULN, severe renal 
impairment 
 
Cytopenias, severe 
renal impairment, 
unanticoagulated 
VTE 
 
Severe cytopenias, 
renal impairment or 
liver impairment, 
current or past 
thrombosis, poor 
performance status 
 
 
 
 
 
Life-expectancy <3 
months, Non-
myeloma related 
cytopenias, liver 
enzymes >2 times 
ULN, severe renal 
impairment, 
impaired LV 
 
 
Not specified 
 
 
 
 
 
 
 
 
No prophylaxis  
 
 
 
 
 
 
Thrombo-
prophylaxis- 
physician discretion 
 
 
 
 
Not specified 
 
 
 
 
 
 
Aspirin 80mg or 
325mg at clinician’s 
discretion OD PO 
 
 
Thrombo-prophylaxis 
was recommended 
initially then 
mandated after the 
1st 266 patients due 
to high VTE rates  
 
 
 
 
 
Aspirin 81mg OD PO 
 
 
 
 
 
 
 
 
 
DVT 4% PE 
1% 
 
 
 
 
 
 
 
LD arm 75% 
VTE rate, 
placebo 0% 
 
 
 
 
VTE 14.7% vs 
3.4% in 
treatment arm 
vs placebo 
 
 
 
11.4% VTE 
vs. 4.6% in 
lenalidomide-
dex arm  
 
 
 
9% 
 
 
 
 
26% in high 
dose dex arm 
and 12% in 
the low dose 
arm 
 
 
 
 
 
 
3% 
 
 
 
 
 
 
 
 
(Knop, et al 2006) 
 
 
 
 
 
(Larocca, et al 
2012) 
 
 
 
 
 
 
(Morgan, et al 
2007) 
 
 
 
 
 
 
(Palumbo, et al 
2007) 
 
 
 
 
 
 
 
(Stewart, et al 
2015) 
41 patients with relapsed 
refractory multiple myeloma 
received lenalidomide, 
adriamycin and 
dexamethasone 
 
342 newly diagnosed 
patients received 
Melphalan, prednisolone 
and lenalidomide plus ASCT 
 
 
 
 
21 heavily pre-treated 
relapsed refractory patients 
received lenalidomide 25mg 
OD days 1-21, 
cyclophosphamide weekly, 
and 40mg dexamethasone 
days 1-4 and 12-15 
 
54 newly diagnosed patients 
received oral mephelan and 
prednisolone days 1-4 and 
lenalidomide days 1-21 
 
 
 
 
 
792 relapsed refractory 
patients received carfilzomib 
with lenalidomide and 
dexamethasone, or 
lenalidomide and 
dexamethasone (low-dose) 
 
Adequate organ 
and bone marrow 
function required 
 
 
 
Excluded if history 
of arterial 
thrombosis or VTE 
in past 12 months, 
contraindication to 
aspirin or LMWH, 
or active bleeding 
 
Not specified 
 
 
 
 
 
 
 
Creatinine 
clearance 
<20mls/min, 
severely deranged 
LFTs, severe 
cytopenias, 
amyloidosis, 
psychiatric illness 
 
Moderate renal 
impairment, 
cytopenias, heart 
failure, grade 3-4 
peripheral 
neuropathy 
 
Not specified 
 
 
 
 
 
Assigned to aspirin 
100mg OD PO or 
enoxaparin 40mg 
OD s/c 
 
 
 
 
Not specified 
 
 
 
 
 
 
 
Aspirin 100mg OD 
PO 
 
 
 
 
 
 
 
All patients received 
thromboprophylaxis- 
not specified 
 
0% 
 
 
 
 
 
2.27% in 
aspirin group, 
1.2% in 
enoxaparin 
group 
 
 
 
14% 
 
 
 
 
 
 
 
4.8% 
 
 
 
 
 
 
 
 
1 yr rate 13% 
in the 
carfilzomib 
arm vs. 6%  
Thalidomide or 
lenalidomide 
(Bradbury 2017) 
 
 
Cyclophosphamide, 
dexamethasone + 
thalidomide or lenalidomide 
+/- ASCT if eligible in 3838 
newly diagnosed patients 
 
 
Grade 2 or worse 
peripheral 
neuropathy, acute 
renal failure 
unresponsive to 
72hrs of 
intravenous fluids 
 
 
Thrombo-prophylaxis 
as per the IMWG 
2008 guidelines  
 
 
11.8%, no sig. 
difference 
between thal 
or len arms 
Pomalidomide 
(Schey, et al 
2004) 
 
 
 
(Streetly, et al 
2005) 
 
 
Pomalidomide 
combination 
therapy 
(Paludo, et al 
2017) 
 
24 relapsed refractory 
patients received escalating 
doses of CC-4047 
(pomalidomide) 
 
15 relapsed refractory 
patients received escalating 
doses of CC-4047 
(pomalidomide) 
 
 
 
50 relapsed refractory 
patients received 
pomalidomide 4mg days 1-
21, weekly bortezomib and 
weekly dexamethasone 
40mg 
 
Severe cytopenias, 
mod renal 
impairment 
 
 
None specified 
 
 
 
 
 
 
DVT not 
anticoagulated, 
poor performance 
status, pregnancy 
 
None 
 
 
 
 
None 
 
 
 
 
 
 
325mg aspirin OD 
PO, or therapeutic 
LMWH or warfarin 
 
1 case- due to 
undiagnosed 
melanoma 
 
 
20% 
 
 
 
 
 
 
10% 
 
  
Pragmatic approach for VTE prophylaxis in myeloma 
Here we provide a pragmatic approach to managing a patient with myeloma who requires 
pharmacological thromboprophylaxis, taking into consideration the risk factors as proposed by the 
IMWG, current available evidence for the use of different anticoagulants in this setting, practicalities of 
managing the type of anticoagulant chosen, and situations where additional thrombotic risks may 
arise, such as the need for surgery, hospitalization and other reasons for poor mobility.  
This approach is based on the available, albeit limited evidence, and would require future review 
and/or modification as new evidence becomes available. It represents the authors opinions only and 
not a formal guideline or recommendation.   
 
We recommend risk stratification based on the IMWG model, with classification of patients into low-
and high-risk groups. Since there are a group of patients who may fail standard dose 
thromboprophylaxis, we propose an additional group, which would be considered as very high-risk. 
This would include patients who have had a previous thrombosis, and those known to have 
antithrombin deficiency. The choice of anticoagulant would be (see Figure 1): 
• Low-risk patients - prophylactic LMWH based on the current available data but aspirin may be 
chosen if patients do not prefer daily injections. Once evidence is available, aspirin may be 
substituted with a DOAC.  
• High-risk patients - prophylactic weight-based LMWH or warfarin with an INR target of 2-3 are 
the drugs of choice. A prophylactic DOAC may be chosen in this group in the context of a 
clinical trial or according to patient wishes after appropriate counselling and consent 
regarding the unlicensed indication. If a DOAC is preferred, meticulous review of concomitant 
interacting medications and contraindications such as renal failure should be performed.  
• Very high-risk patients - after assessment of bleeding risk and adjustment of any modifiable 
risk factors, a high prophylactic dose of LMWH (target anti-Xa of 0.4-.0.6 IU/ml) or therapeutic 
dose LMWH may be chosen until the period of greatest thromboembolic risk has passed. 
Given the evidence provide by Myeloma XI that the vast majority of VTEs occurred within the 
initial 6 month induction period, this may be a practical timeframe to apply (Bradbury 2017, C. 
A. Bradbury 2018).  
 Figure 1. Thrombosis risk assessment and anticoagulant choice in newly diagnosed multiple 
myeloma 
 
The duration of thromboprohylaxis has not been adequately studied but at least six months from the 
initial diagnosis is preferable. If IMiD-based treatment is being continued in the absence of high-dose 
dexamethasone or other chemotherapies, continued thromboprophylaxis should be discussed with 
the patient. This may be with aspirin, a DOAC or even continued prophylactic LMWH. In all cases, the 
dosing may need altering based on patient’s initial risks of bleeding or thrombosis, and at regular 
intervals. For example, if the patient’s mobility is restricted following myeloma-related fracture, a 
higher dose may need consideration, whereas renal impairment or thrombocytopenia may necessitate 
dose reduction. 
 
Special considerations 
 
Renal disease 
 
Renal disease in multiple myeloma is common and variable, ranging from patients with mild 
proteinuria, to the nephrotic syndrome, with or without renal impairment. Renal failure occurs in 50% 
of patients during the course of their disease (Clark, et al 1999), yet patients with end-stage renal 
failure are poorly represented in trials. It is a prothrombotic state, with a multifactorial aetiology, due to 
prothrombotic changes in the vascular endothelium, increased levels of inflammatory procoagulant 
factors and alterations in platelet physiology (Hughes, et al 2014). In patients with myeloma, and 
especially those with AL amyloidosis, proteinuria can contribute to increased thrombotic tendency, 
and this is most marked in those with nephrotic-grade proteinuria. Bever et al. reviewed 929 patients 
with AL amyloidosis presenting to a single-centre over a 10-year period, of whom 7% had 
documented VTE (Bever, et al 2016). A non-significant increase in VTE risk was observed if serum 
albumin was 30-40 g/dl (hazard ratio 2.16, CI 0.80-5.81). Patients with serum albumin of less than 30 
g/dl, however had a hazard ratio of 4.30 for the development of thrombosis which was statistically 
significant (CI 1.60-11.55, p=0.0038). increasing levels of proteinuria were also associated with 
increased VTE risk, although this only reached statistical significance at levels of more than 8g per 
day. Of 382 cases with nephrotic-grade proteinuria, VTE rate was 9.7%. Serum albumin level is 
inversely correlated with urinary protein loss, not only of albumin but also important endogenous 
antithrombotic proteins, in particular antithrombin III (AT). Overall, the studies on AL amyloidosis 
patient have found similar rates of thrombosis to those seen in myeloma, with high associated 
mortality noted (1 month mortality 20% in 1 study) (Halligan, et al 2006, Srkalovic, et al 2005). Given 
the association between nephrotic-grade proteinuria and clinically significant antithrombin deficiency, 
assessment of urine is important in myeloma patients not purely for the detection of M-proteins and 
light chains. Patients with documented AT deficiency and thrombosis provide an even greater 
management challenge (they are at extremely high risk of thrombosis and may require LMWH dosing 
alterations, as LMWH works by potentiating AT). We would suggest AT deficiency is worth excluding 
in those with thrombosis in the context of significant proteinuria (Kumar, et al 2012), and concurrent 
AL amyloidosis should be considered in these patients. This is of additional relevance due to the 
haemorrhagic deficiencies seen in amyloidosis. These have been more extensively studied than the 
thrombotic issues, and involve defective vascular integrity, acquired factor X deficiency and acquired 
von Willebrand syndrome (Bever, et al 2016), and clearly have to be borne in mind when managing 
thrombotic risk in affected individuals.  
 
Separate to proteinuria and the nephrotic syndrome, chronic renal impairment is not only a risk factor 
for thrombosis, but subsequent anticoagulation also poses challenges in this demographic, who are at 
greater risk of haemorrhagic complications (Parker et al 2018). Most bleeding risk assessment scores 
include renal impairment as a risk factor. Analysis of over 14,000 patients enrolled in the RIETE 
registry (Registro Informatizado de Enfermedad Thrombo Embolica) reported that, of the 20% who 
had active cancer, rates of fatal pulmonary embolism (PE) and fatal bleeding were increased 
compared to patients without malignancy, and renal insufficiency was identified as one of several 
independent risk factors for mortality (Trujillo-Santos, et al 2009). 
 
In relation to anticoagulant treatment in patients with cancer and co-existing renal impairment, data 
from the CLOT trial (Lee, et al 2003) was reviewed in patients with moderate (CrCl 30-60ml/min) or 
severe (CrCl<30ml/min) renal impairment. 24% of the total group had some degree of renal 
impairment, but only 2% met criteria for ‘severe’ impairment. Major and minor bleeding episodes 
occurred in 20% in the dalteparin group versus 24% of VKA-treated patients with significantly more 
VTE recurrences in the VTE group (17% versus 3%). Although based on this data, LMWH was 
concluded to be superior to warfarin in patients with cancer and renal impairment; patients with a 
creatinine three times or more above the upper limit of normal were excluded from the study. If LMWH 
is chosen in this setting, it also needs to be borne in mind that the various LMWHs are not identical in 
terms of their pharmacokinetic profiles in renal insufficiency. Prophylactic doses of enoxaparin have 
been shown to accumulate in patients with CrCl<30ml/min, whereas tinzaparin and dalteparin do not. 
For this reason, dose reductions or monitoring might be required if enoxaparin is chosen (Atiq, et al 
2015). Monitoring using an anti-Xa assay calibrated to LMWH is essential and is recommended in all 
antithrombotic therapy guidelines, with a target trough level of 0.1-0.3 IU/ml and peak of 0.5-1.0 IU/ml 
for treatment, while a peak level of 0.1-0.3 IU/ml would be ideal for prophylaxis (Hughes, et al 2014). 
 
VKAs are not renally excreted, being metabolised by cytochrome P450 enzymes. However, renal 
failure causes downregulation of enzymatic activity and can therefore still alter warfarin’s 
pharmacokinetic profile (Limdi, et al 2010). This may partly explain the poor INR control seen in 
patients with severe renal failure on warfarin (Chaaban, et al 2015, Kai, et al 2017, Yang, et al 2017), 
providing additional evidence against the use of VKAs in this setting. Furthermore, alongside the 
evidence of inferiority to LMWH, meta-analysis of studies comparing DOACs to VKAs has shown 
fewer haemorrhagic complications with DOACs in patients with moderate renal impairment (CrCl 30-
50ml/min) (van Es, et al 2014). 
 
The DOACs in common usage have different licenses with respect to treatment of VTE in renal 
impairment. This has recently been reviewed (Parker, et al 2018). Specifically in relation to myeloma, 
rivaroxaban and apixaban are highly protein-bound in circulation, and therefore affected by 
hypoalbuminaemia which may develop in renal failure patients with proteinuria or nutritional 
deficiency. Since patients with renal impairment may require other drugs in addition to those specific 
for myeloma, and the fact that all four DOACs are to some extent metabolized by cytochrome P450 
enzymes, careful drug selection is required. If a DOAC is chosen, close attention to drug monitoring 
may be necessary in this setting (Parker, et al 2018). Betrixaban, the most recent anti-Xa inhibitor on 
the market has the lowest renal clearance at only 11% and is not metabolized by the CYP 450 
system. It has been FDA-approved for VTE prophylaxis in those with CrCl15 mls/min without severe 
liver impairment (Huisman and Klok 2018). It has not yet been approved for prophylaxis by the EMA, 
and while it offers a potentially attractive future option for use in patients with renal failure, it should be 
noted that its long half-life (approximately 37 hours) may be of concern in those with a high bleeding 
risk.  
 
Recurrent thrombosis 
 
There is a paucity of data on how best to manage recurrent VTE in cancer patients, and even less in 
those with myeloma specifically. What is abundantly clear, is that patients with cancer have high 
recurrence rates despite anticoagulation of any form eg. In the Hokusai trial, 7.9% of edoxaban or 
11.3% of dalteparin patients suffered a further VTE (Raskob, et al 2018). These rates are similar to 
those seen in patients with unprovoked events who discontinue anticoagulation. Similar findings have 
been seen in myeloma trials. In a cohort of 256 newly diagnosed myeloma patients, where LMWH, 
(enoxaparin 40 mg daily) was instituted as DVT prophylaxis in the thalidomide-treated patients (n = 
68), DVT recurred in four patients (11%) (Zangari, et al 2004a), and the majority of patients in 
Myeloma XI (over 4000 patients in all) were on thromboprophyaxis at the time of VTE (Bradbury 
2017, C. A. Bradbury 2018). This means that prophylactic LMWH does not fully eliminate the 
thrombotic risk in myeloma. The ISTH issued recommendations for patients with malignancy who 
suffer recurrent thrombosis on anticoagulation, giving the following options - switching from a VKA to 
LMWH, increasing the dose of LMWH by 20-25% if already in use, or to consider insertion of an 
inferior vena cava filter (Farge, et al 2016). These recommendations were based on results of a small, 
70 patient, retrospective cohort study of patients with VTE on anticoagulation, alongside expert 
opinion in lieu of robust evidence. In this study, those on warfarin or prophylactic dose LMWH 
switched to therapeutic dose LMWH, whereas those on treatment dose LMWH received a 20-25% 
dose escalation for at least 4 weeks. Despite this, 8.6% of the cohort had a further VTE during a 
minimum of only 3 months follow up, and it should be noted that the group’s median survival was less 
than one year (Carrier, et al 2009). General measures including assessment of compliance to 
pharmacological thromboprophylaxis, consideration of other prothrombotic conditions for example 
heparin-induced thrombocytopenia, and presence of mechanical compression from tumour masses 
are also routinely advised (Romualdi and Ageno 2016). For those on oral agents, gastrointestinal 
absorption should be reviewed alongside possible interactions with other medications being 
administered.  
 
Most of the available information with respect to ‘failure of anticoagulation’ pertains to VKAs and 
LMWH. The Hokusai (Raskob, et al 2018) and SELECT-D (Young, et al 2018) trials provide evidence 
in support of use of DOACs in the therapeutic setting but are not specific to myeloma, nor VTE 
recurrence. 9% of the Hokusai group had a prior history of VTE, but whether this was in the context of 
malignancy is not known, and patients on therapeutic anticoagulation at time of thrombosis are 
specifically excluded. A case report of successful management of a myeloma patient with VTE on 
prophylactic aspirin and erratic INR control on warfarin was recently published (Oka, et al 2017), and 
it is likely that DOACs are being used more frequently in clinical practice in this setting.  
 
The ISTH set up an international registry to increase the available data regarding this issue. 212 
cancer patients with a recurrence of VTE despite anticoagulation with either unfractionated heparin, 
LMWH, fondaparinux or a VKA were monitored for 3 months. A small proportion (8%) had leukaemia, 
lymphoma or myeloma. 70% of the cohort had been therapeutically or supra-therapeutically 
anticoagulated at the time of VTE. 11% had a further event during follow-up, 8% had major bleeding 
and 27% died. Increasing anticoagulation intensity had no beneficial effect on recurrence rate, or a 
significant association with increased haemorrhagic complications. As seen previously, rate of 
recurrence was higher with VKAs than LMWH (Schulman, et al 2015).  
 
Evaluation of whether anticoagulation is in the therapeutic range is traditionally achieved using 
standard laboratory investigations eg. the International Normalized Ratio (INR) for VKA and anti-Xa 
levels for LMWH. However, use of global measures of coagulation may provide further, relevant 
information regarding the patient’s overall haemostatic state. One group used thromboelastography 
(TEG), thrombin generation test (TGT), thrombodynamics (TD) and some standard laboratory 
parameters such as D-dimer levels, fibrinogen, activated partial prothrombin time (APTT) and 
prothrombin time (PT) in MM patients at diagnosis, during stem cell mobilisation, and in remission 
(Gracheva, et al 2015). D-dimer was significantly elevated, and global haemostasis tests showed 
patients to be hypercoagulable compared with normal controls whether at diagnosis or in remission. 
However, there was significant heterogeneity of results with some patients also demonstrated to be 
hypocoagulable. Patients undergoing stem cell mobilisation received infusional unfractionated heparin 
as VTE prophylaxis. Importantly, in 22%, at least 2 of the global tests of haemostasis showed no 
hypocoagulable features despite APTT levels in the target range, and some remained 
hypercoagulable suggesting a significant proportion of the patients assessed had evidence of 
heparin-resistance. If this finding were reproduced in a larger sample size, particularly in patients 
receiving LMWH, it would provide concerning evidence of lack of efficacy of current 
thromboprophylactic measures, at least in a subset of patients, which may be contributing to ongoing 
rates of VTE despite anticoagulation. It is likely that anti-Xa levels may not be fully reflective of global 
haemostasis in patients with recurrent VTE despite seemingly therapeutic LMWH anticoagulation, and 
more information is required regarding the practical utility of global tests of haemostasis in managing 
these challenging patients.  
 
The findings from the ISTH registry along with evidence of heparin resistance in a significant minority 
of patients, suggests that therapeutic doses of LMWH do not offer sufficient protection for a subset of 
myeloma patients, and that mere dose escalation may not be an adequate strategy. Our approach in 
these patients is summarized in Figure 2. with suggestions for patients who may have been on 
warfarin, LMWH or a DOAC. Since currently, no better approaches are available in patients who are 
on therapeutic doses of LMWH who developed recurrent clots; we would choose the split dose 
strategy (ie. The full weight-based dose divided into two doses, given at 12 hour intervals) in addition 
to modifying thrombotic risk factors (mobilization, temporary interruption of IMiDs etc). Some of the 
rare causes of recurrent thrombosis on anticoagulation include antiphospholipid syndrome, vasculitis, 
vascular malformations and hyperhomocystenemia, which require due consideration (Thachil 2012).  
 
 Figure 2. Management of anticoagulation in recurrent thrombosis 
 
 
Spinal cord compression 
 
Spinal cord compression may occur in patients with myeloma as a result of vertebral lytic lesions or 
growth of compressive soft tissue masses. VTE risk in these patients is markedly increased by the 
combination of immobility, and need for surgical interventions, venous stasis due to loss of contraction 
of lower limb muscles, inflammatory prothrombotic changes stimulated by tissue damage, alongside 
all the usual myeloma-related risk factors. Reported rates of VTE in spinal cord injury are as high as 
50% of patients (Teasell, et al 2009). Specific guidance relating to spinal cord compression in 
myeloma patients is lacking, however the NICE recommendations on management of metastatic 
spinal cord compression suggest mechanical thromboprophylaxis with thigh-high graduated 
compression stockings, unless contraindication eg. by sensory loss, or intermittent pneumatic 
compression devices with concomitant LMWH prophylaxis. Duration of thromboprophylaxis should be 
based on individual risk assessment, overall clinical condition, and whether the patient has regained 
normal mobility (NICE Clinical guidelines 2008).  
 
Future directions 
 
Management of multiple myeloma has developed significantly in recent years with patients surviving 
for many years more than previously reported (Kumar, et al 2008). However, in this era of novel 
agents, patients are still dying from VTE-related complications, and despite current 
thromboprophylactic approaches, a significant proportion of patients are still expected to develop 
thromboembolic disease as a sequelae of myeloma or its treatment, with those at highest risk not fully 
protected by the pharmacological agents administered as part of modern treatment protocols. The 
current recommendation for thromboprophylaxis in patients receiving IMiD-based regimens is low-
dose aspirin if at low risk of thrombosis and LMWH if at high-risk, as per the IMWG 2008 model. If 
future models allow improved identification of those at the highest risk, either through use of novel 
thrombosis biomarkers, point of care testing, or presence of numerous clinical risk factors, 
thromboprophylaxis measures will need to adapt to reflect this, following confirmation of safety and 
efficacy in prospective RCTs. Data from the Hokusai trial suggests that DOACs may possibly confer 
greater protection than LMWH (Raskob, et al 2018), based on the reduction of VTE seen, however 
this evidence does not pertain to primary VTE prevention, nor is specific to myeloma, and further 
information is needed in order to improve management of these patients. Similarly more work can 
only provide us with better knowledge on how to deal with the special situations of renal impairment 
and spinal cord compression, where the risk of both thrombosis and haemorrhage are increased and 
carefully weighing the risks and benefits are crucial.  
 
 
 
DS performed the literature review, wrote the first draft and made the edits for the final version. AR 
and CB critically reviewed the manuscript. JT conceived the review and critically reviewed the 
manuscript. All the authors approved the final version submitted 
 
Conflicts of interest: JT has received honoraria from BMS-Pfizer, Boehringer, Bayer and Daichii. 
Sankyo whose products are mentioned in the paper. CB has received honoraria from BMS-Pfizer and 
Novartis. 
 
References 
 
 
Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M., Porcari, A., 
Raskob, G.E. & Weitz, J.I. (2013) Apixaban for extended treatment of venous 
thromboembolism. N Engl J Med, 368, 699-708. 
Al-Ani, F., Bermejo, J.M., Mateos, M.V. & Louzada, M. (2016) Thromboprophylaxis in 
multiple myeloma patients treated with lenalidomide - A systematic review. Thromb 
Res, 141, 84-90. 
Ambrus, J.L., Ambrus, C.M., Mink, I.B. & Pickren, J.W. (1975) Causes of death in cancer 
patients. J Med, 6, 61-64. 
Amrani, D.L. (1990) Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 
control. Blood Coagul Fibrinolysis, 1, 443-446. 
Atiq, F., van den Bemt, P.M., Leebeek, F.W., van Gelder, T. & Versmissen, J. (2015) A 
systematic review on the accumulation of prophylactic dosages of low-molecular-
weight heparins (LMWHs) in patients with renal insufficiency. Eur J Clin Pharmacol, 
71, 921-929. 
Auwerda, J.J., Sonneveld, P., de Maat, M.P. & Leebeek, F.W. (2007) Prothrombotic 
coagulation abnormalities in patients with newly diagnosed multiple myeloma. 
Haematologica, 92, 279-280. 
Ay, C., Simanek, R., Vormittag, R., Dunkler, D., Alguel, G., Koder, S., Kornek, G., Marosi, 
C., Wagner, O., Zielinski, C. & Pabinger, I. (2008) High plasma levels of soluble P-
selectin are predictive of venous thromboembolism in cancer patients: results from the 
Vienna Cancer and Thrombosis Study (CATS). Blood, 112, 2703-2708. 
Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., 
Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. & Tricot, 
G. (2001) Extended survival in advanced and refractory multiple myeloma after 
single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 
patients. Blood, 98, 492-494. 
Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., 
Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, 
S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. 
(1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. 
Blood, 93, 55-65. 
Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, 
A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., 
Kiwan, E., Krishna, S., Fox, M. & Crowley, J. (2006) Thalidomide and 
hematopoietic-cell transplantation for multiple myeloma. N Engl J Med, 354, 1021-
1030. 
Baz, R., Li, L., Kottke-Marchant, K., Srkalovic, G., McGowan, B., Yiannaki, E., Karam, 
M.A., Faiman, B., Jawde, R.A., Andresen, S., Zeldis, J. & Hussein, M.A. (2005) The 
role of aspirin in the prevention of thrombotic complications of thalidomide and 
anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc, 80, 1568-
1574. 
Baz, R., Walker, E., Karam, M.A., Choueiri, T.K., Jawde, R.A., Bruening, K., Reed, J., 
Faiman, B., Ellis, Y., Brand, C., Srkalovic, G., Andresen, S., Knight, R., Zeldis, J. & 
Hussein, M.A. (2006) Lenalidomide and pegylated liposomal doxorubicin-based 
chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann 
Oncol, 17, 1766-1771. 
Bellotti, V., Gamba, G., Merlini, G., Montani, N., Bucciarelli, E., Stoppini, M. & Ascari, E. 
(1989) Study of three patients with monoclonal gammopathies and 'lupus-like' 
anticoagulants. Br J Haematol, 73, 221-227. 
Bennett, C.L., Schumock, G.T., Desai, A.A., Kwaan, H.C., Raisch, D.W., Newlin, R. & 
Stadler, W. (2002) Thalidomide-associated deep vein thrombosis and pulmonary 
embolism. Am J Med, 113, 603-606. 
Bever, K.M., Masha, L.I., Sun, F., Stern, L., Havasi, A., Berk, J.L., Sanchorawala, V., Seldin, 
D.C. & Sloan, J.M. (2016) Risk factors for venous thromboembolism in 
immunoglobulin light chain amyloidosis. Haematologica, 101, 86-90. 
Blom, J.W., Doggen, C.J., Osanto, S. & Rosendaal, F.R. (2005) Malignancies, prothrombotic 
mutations, and the risk of venous thrombosis. Jama, 293, 715-722. 
Bradbury, C. (2017) Thrombotic Events in Patients with Myeloma Treated with 
Immunomodulatory Drugs; Results of the Myeloma XI Study. Vol. 130, p. 553. 
C. A. Bradbury, M.J., A. Striha, G. Cook, C. Pawlyn, J. Jones, D. Cairns, A. Hockaday, A. 
Paterson, M. Drayson, R. Owen, M. Kaiser, W. Gregory, F. Davis, G. Morgan, G. 
Jackson (2018) Thrombotic events in patients with Myeloma treated with 
Immunomodulatory drugs; Results of the Myeloma XI Study. Br J Haematol, 181, 
S1. 
Carrier, M., Le Gal, G., Cho, R., Tierney, S., Rodger, M. & Lee, A.Y. (2009) Dose escalation 
of low molecular weight heparin to manage recurrent venous thromboembolic events 
despite systemic anticoagulation in cancer patients. J Thromb Haemost, 7, 760-765. 
Cavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., Testoni, N., Tonelli, 
M., de Vivo, A., Palareti, G., Tura, S. & Baccarani, M. (2004) First-line therapy with 
thalidomide and dexamethasone in preparation for autologous stem cell 
transplantation for multiple myeloma. Haematologica, 89, 826-831. 
Chaaban, A., Gebran, N., Abdelmegid, K.,, Abouchacra, S., Soliman, K., Agha, L. & Butt, & 
L (2015) Effectiveness and safety of warfarin 
use for cardiac indications in hemodialysis 
patients. . Nephrology Dialysis Transplant, 30, 563-564. 
Chalayer, E., Bourmaud, A., Tinquaut, F., Chauvin, F. & Tardy, B. (2016a) Cost-
effectiveness analysis of low-molecular-weight heparin versus aspirin 
thromboprophylaxis in patients newly diagnosed with multiple myeloma. Thromb 
Res, 145, 119-125. 
Chalayer, E., Chapelle, C., Leleu, X., Elalamy, I., Laporte, S. & Tardy, B. (2016b) Does the 
choice of thrombotic prophylactic drug depend on the known risk factors of patients 
with multiple myeloma in clinical practice? Thromb Res, 143, 101-102. 
Clark, A.D., Shetty, A. & Soutar, R. (1999) Renal failure and multiple myeloma: 
pathogenesis and treatment of renal failure and management of underlying myeloma. 
Blood Rev, 13, 79-90. 
Corso, A., Lorenzi, A., Terulla, V., Airo, F., Varettoni, M., Mangiacavalli, S., Zappasodi, P., 
Rusconi, C. & Lazzarino, M. (2004) Modification of thrombomodulin plasma levels 
in refractory myeloma patients during treatment with thalidomide and 
dexamethasone. Ann Hematol, 83, 588-591. 
Dimopoulos, M., Spencer, A., Attal, M., Prince, H.M., Harousseau, J.L., Dmoszynska, A., 
San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, 
M., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus 
dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med, 357, 
2123-2132. 
Dimopoulos, M.A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., 
Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., Gika, D., 
Panayiotidis, P., Christakis, I. & Anagnostopoulos, N. (2001) Thalidomide and 
dexamethasone combination for refractory multiple myeloma. Ann Oncol, 12, 991-
995. 
Donati, M.B. (1994) Cancer and thrombosis. Haemostasis, 24, 128-131. 
Dong, R., Ma, G., Zhang, S., Gao, Y., Liu, S. & Su, Y. (2018) Simvastatin reverses multiple 
myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 
signalling pathway. Blood Coagul Fibrinolysis, 29, 501-508. 
Eby, C. (2009) Pathogenesis and management of bleeding and thrombosis in plasma cell 
dyscrasias. Br J Haematol, 145, 151-163. 
Elice, F., Fink, L., Tricot, G., Barlogie, B. & Zangari, M. (2006) Acquired resistance to 
activated protein C (aAPCR) in multiple myeloma is a transitory abnormality 
associated with an increased risk of venous thromboembolism. Br J Haematol, 134, 
399-405. 
Esmon, C.T. (2001) Protein C anticoagulant pathway and its role in controlling microvascular 
thrombosis and inflammation. Crit Care Med, 29, S48-51; discussion 51-42. 
Falanga, A. & Marchetti, M. (2009) Venous thromboembolism in the hematologic 
malignancies. J Clin Oncol, 27, 4848-4857. 
Farge, D., Bounameaux, H., Brenner, B., Cajfinger, F., Debourdeau, P., Khorana, A.A., 
Pabinger, I., Solymoss, S., Douketis, J. & Kakkar, A. (2016) International clinical 
practice guidelines including guidance for direct oral anticoagulants in the treatment 
and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol, 
17, e452-e466. 
Gado, K., Domjan, G., Hegyesi, H. & Falus, A. (2000) Role of INTERLEUKIN-6 in the 
pathogenesis of multiple myeloma. Cell Biol Int, 24, 195-209. 
Gracheva, M.A., Urnova, E.S., Sinauridze, E.I., Tarandovskiy, I.D., Orel, E.B., Poletaev, 
A.V., Mendeleeva, L.P., Ataullakhanov, F.I. & Balandina, A.N. (2015) 
Thromboelastography, thrombin generation test and thrombodynamics reveal 
hypercoagulability in patients with multiple myeloma. Leuk Lymphoma, 56, 3418-
3425. 
guidelines, N.C. (2018) Venous thromboembolism in over 16s: reducing the risk of hospital-
acquired deep vein thrombosis or pulmonary embolism. 
Guo, L., Tong, D., Yu, M., Zhang, Y., Li, T., Wang, C., Zhou, P., Jin, J., Li, B., Liu, Y., Liu, 
R., Novakovic, V.A., Dong, Z., Tian, Y., Kou, J., Bi, Y., Zhou, J. & Shi, J. (2018) 
Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients 
with multiple myeloma. Int J Oncol, 52, 1981-1990. 
Halligan, C.S., Lacy, M.Q., Vincent Rajkumar, S., Dispenzieri, A., Witzig, T.E., Lust, J.A., 
Fonseca, R., Gertz, M.A., Kyle, R.A. & Pruthi, R.K. (2006) Natural history of 
thromboembolism in AL amyloidosis. Amyloid, 13, 31-36. 
Hiroi, T., Deming, C.B., Zhao, H., Hansen, B.S., Arkenbout, E.K., Myers, T.J., McDevitt, 
M.A. & Rade, J.J. (2009) Proteasome inhibitors enhance endothelial thrombomodulin 
expression via induction of Kruppel-like transcription factors. Arterioscler Thromb 
Vasc Biol, 29, 1587-1593. 
Hughes, S., Szeki, I., Nash, M.J. & Thachil, J. (2014) Anticoagulation in chronic kidney 
disease patients-the practical aspects. Clin Kidney J, 7, 442-449. 
Huisman, M.V. & Klok, F.A. (2018) Pharmacological properties of betrixaban. Eur Heart J 
Suppl, 20, E12-e15. 
Johannesdottir, S.A., Horváth-Puhó, E., Dekkers, O.M. & et al. (2013) Use of glucocorticoids 
and risk of venous thromboembolism: A nationwide population-based case-control 
study. JAMA Internal Medicine, 173, 743-752. 
Kai, B., Bogorad, Y., Nguyen, L.N., Yang, S.J., Chen, W., Spencer, H.T., Shen, A.Y. & Lee, 
M.S. (2017) Warfarin use and the risk of mortality, stroke, and bleeding in 
hemodialysis patients with atrial fibrillation. Heart Rhythm, 14, 645-651. 
Katodritou, E., Vadikolia, C., Lalagianni, C., Kotsopoulou, M., Papageorgiou, G., Kyrtsonis, 
M.C., Matsouka, P., Giannakoulas, N., Kyriakou, D., Karras, G., Anagnostopoulos, 
N., Michali, E., Briasoulis, E., Hatzimichael, E., Spanoudakis, E., Zikos, P., 
Tsakiridou, A., Tsionos, K., Anargyrou, K., Symeonidis, A., Maniatis, A. & Terpos, 
E. (2014) "Real-world" data on the efficacy and safety of lenalidomide and 
dexamethasone in patients with relapsed/refractory multiple myeloma who were 
treated according to the standard clinical practice: a study of the Greek Myeloma 
Study Group. Ann Hematol, 93, 129-139. 
Kerachian, M.A., Cournoyer, D., Harvey, E.J., Chow, T.Y., Neagoe, P.E., Sirois, M.G. & 
Seguin, C. (2009) Effect of high-dose dexamethasone on endothelial haemostatic 
gene expression and neutrophil adhesion. J Steroid Biochem Mol Biol, 116, 127-133. 
Khorana, A.A., Francis, C.W., Culakova, E., Kuderer, N.M. & Lyman, G.H. (2007) 
Thromboembolism is a leading cause of death in cancer patients receiving outpatient 
chemotherapy. J Thromb Haemost, 5, 632-634. 
Khorana, A.A., Kamphuisen, P.W., Meyer, G., Bauersachs, R., Janas, M.S., Jarner, M.F. & 
Lee, A.Y. (2017) Tissue Factor As a Predictor of Recurrent Venous 
Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. J Clin 
Oncol, 35, 1078-1085. 
Knop, S., Gerecke, C., Topp, M.S., Liebisch, P., Hess, G., Kotkiewitz, S., Einsele, H. & 
Bargou, R. (2006) Lenalidomide (Revlimid™), Adriamycin and Dexamethasone 
Chemotherapy (RAD) Is Safe and Effective in Treatment of Relapsed Multiple 
Myeloma - First Results of a German Multicenter Phase I/II Trial. Blood, 108, 408-
408. 
Kotlin, R., Sobotkova, A., Riedel, T., Salaj, P., Suttnar, J., Reicheltova, Z., Majek, P., 
Khaznadar, T. & Dyr, J.E. (2008) Acquired dysfibrinogenemia secondary to multiple 
myeloma. Acta Haematol, 120, 75-81. 
Kristen Marie Sanfilippo, T.-F.W., Suhong Luo, Kenneth Robert Carson, Theodore Seth 
Thomas, Brian Gage (2018) Prediction of venous thromboembolism (VTE) in 
multiple myeloma (MM): Myeloma clot score (MCS). J Clin Oncol, suppl; abstr 
6585. 
Kristinsson, S.Y., Fears, T.R., Gridley, G., Turesson, I., Mellqvist, U.H., Bjorkholm, M. & 
Landgren, O. (2008) Deep vein thrombosis after monoclonal gammopathy of 
undetermined significance and multiple myeloma. Blood, 112, 3582-3586. 
Kristinsson, S.Y., Pfeiffer, R.M., Bjorkholm, M., Goldin, L.R., Schulman, S., Blimark, C., 
Mellqvist, U.H., Wahlin, A., Turesson, I. & Landgren, O. (2010) Arterial and venous 
thrombosis in monoclonal gammopathy of undetermined significance and multiple 
myeloma: a population-based study. Blood, 115, 4991-4998. 
Kumar, S., Chapagain, A., Nitsch, D. & Yaqoob, M.M. (2012) Proteinuria and 
hypoalbuminemia are risk factors for thromboembolic events in patients with 
idiopathic membranous nephropathy: an observational study. BMC Nephrology, 13, 
107. 
Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., 
Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & 
Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel 
therapies. Blood, 111, 2516-2520. 
Lacy, M.Q., Hayman, S.R., Gertz, M.A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P.R., 
Lust, J.A., Russell, S.J., Dingli, D., Kyle, R.A., Fonseca, R., Bergsagel, P.L., Roy, V., 
Mikhael, J.R., Stewart, A.K., Laumann, K., Allred, J.B., Mandrekar, S.J. & Rajkumar, 
S.V. (2009) Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for 
relapsed multiple myeloma. J Clin Oncol, 27, 5008-5014. 
Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., 
Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., Patriarca, F., Cavo, M., 
Peccatori, J., Catalano, L., Carella, A.M., Cafro, A.M., Siniscalchi, A., Crippa, C., 
Petrucci, M.T., Yehuda, D.B., Beggiato, E., Di Toritto, T.C., Boccadoro, M., Nagler, 
A. & Palumbo, A. (2012) Aspirin or enoxaparin thromboprophylaxis for patients with 
newly diagnosed multiple myeloma treated with lenalidomide. Blood, 119, 933-939; 
quiz 1093. 
Lee, A.Y., Levine, M.N., Baker, R.I., Bowden, C., Kakkar, A.K., Prins, M., Rickles, F.R., 
Julian, J.A., Haley, S., Kovacs, M.J. & Gent, M. (2003) Low-molecular-weight 
heparin versus a coumarin for the prevention of recurrent venous thromboembolism in 
patients with cancer. N Engl J Med, 349, 146-153. 
Leleu, X., Rodon, P., Hulin, C., Daley, L., Dauriac, C., Hacini, M., Decaux, O., Eisemann, 
J.C., Fitoussi, O., Lioure, B., Voillat, L., Slama, B., Al Jijakli, A., Benramdane, R., 
Chaleteix, C., Costello, R., Thyss, A., Mathiot, C., Boyle, E., Maloisel, F., Stoppa, 
A.M., Kolb, B., Michallet, M., Lamblin, A., Natta, P., Facon, T., Elalamy, I., 
Fermand, J.P. & Moreau, P. (2013) MELISSE, a large multicentric observational 
study to determine risk factors of venous thromboembolism in patients with multiple 
myeloma treated with immunomodulatory drugs. Thromb Haemost, 110, 844-851. 
Li, W., Garcia, D., Cornell, R.F., Gailani, D., Laubach, J., Maglio, M.E., Richardson, P.G. & 
Moslehi, J. (2017) Cardiovascular and Thrombotic Complications of Novel Multiple 
Myeloma Therapies: A Review. JAMA Oncol, 3, 980-988. 
Limdi, N.A., Limdi, M.A., Cavallari, L., Anderson, A.M., Crowley, M.R., Baird, M.F., 
Allon, M. & Beasley, T.M. (2010) Warfarin dosing in patients with impaired kidney 
function. Am J Kidney Dis, 56, 823-831. 
Lonial, S., Richardson, P.G., San Miguel, J., Sonneveld, P., Schuster, M.W., Blade, J., 
Cavenagh, J., Rajkumar, S.V., Jakubowiak, A.J., Esseltine, D.L., Anderson, K.C. & 
Harousseau, J.L. (2008) Characterisation of haematological profiles and low risk of 
thromboembolic events with bortezomib in patients with relapsed multiple myeloma. 
Br J Haematol, 143, 222-229. 
Man, L., Morris, A., Brown, J., Palkimas, S. & Davidson, K. (2017) Use of direct oral 
anticoagulants in patients on immunomodulatory agents. J Thromb Thrombolysis, 44, 
298-302. 
McLawhorn, A.S., Beathe, J., YaDeau, J., Buschiazzo, V., Purdue, P.E., Ma, Y., Sculco, T.P. 
& Jules-Elysee, K. (2015) Effects of steroids on thrombogenic markers in patients 
undergoing unilateral total knee arthroplasty: a prospective, double-blind, randomized 
controlled trial. J Orthop Res, 33, 412-416. 
Mechtcheriakova, D., Wlachos, A., Holzmuller, H., Binder, B.R. & Hofer, E. (1999) 
Vascular endothelial cell growth factor-induced tissue factor expression in endothelial 
cells is mediated by EGR-1. Blood, 93, 3811-3823. 
Menon, S.P., Rajkumar, S.V., Lacy, M., Falco, P. & Palumbo, A. (2008) Thromboembolic 
events with lenalidomide-based therapy for multiple myeloma. Cancer, 112, 1522-
1528. 
Morgan, G.J., Schey, S.A., Wu, P., Srikanth, M., Phekoo, K.J., Jenner, M. & Davies, F.E. 
(2007) Lenalidomide (Revlimid), in combination with cyclophosphamide and 
dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br 
J Haematol, 137, 268-269. 
Nayak, L., Shi, H., Atkins, G.B., Lin, Z., Schmaier, A.H. & Jain, M.K. (2014) The 
thromboprotective effect of bortezomib is dependent on the transcription factor 
Kruppel-like factor 2 (KLF2). Blood, 123, 3828-3831. 
NICE Clinical guidelines, N. (2008) National Collaborating centre for cancer (UK). 
Metastatic spinal cord compression: diagnosis and management of patients at risk of 
or with metastatic spinal cord compression. 
NICE Clinical guidelines, N. (2016) Myeloma: diagnosis and management. 
O'Kane, M.J., Wisdom, G.B., Desai, Z.R. & Archbold, G.P. (1994) Inhibition of fibrin 
monomer polymerisation by myeloma immunoglobulin. J Clin Pathol, 47, 266-268. 
Oka, S., Takeuchi, S., Shiragami, H., Hamahata, K. & Nohgawa, M. (2017) Successful 
management of venous thromboembolism with apixaban in a multiple myeloma 
patient on lenalidomide therapy. Rinsho Ketsueki, 58, 37-41. 
Paludo, J., Mikhael, J.R., LaPlant, B.R., Halvorson, A.E., Kumar, S., Gertz, M.A., Hayman, 
S.R., Buadi, F.K., Dispenzieri, A., Lust, J.A., Kapoor, P., Leung, N., Russell, S.J., 
Dingli, D., Go, R.S., Lin, Y., Gonsalves, W.I., Fonseca, R., Bergsagel, P.L., Roy, V., 
Sher, T., Chanan-Khan, A.A., Ailawadhi, S., Stewart, A.K., Reeder, C.B., 
Richardson, P.G., Rajkumar, S.V. & Lacy, M.Q. (2017) Pomalidomide, bortezomib, 
and dexamethasone for patients with relapsed lenalidomide-refractory multiple 
myeloma. Blood, 130, 1198-1204. 
Palumbo, A., Bertola, A., Falco, P., Rosato, R., Cavallo, F., Giaccone, L., Bringhen, S., 
Musto, P., Pregno, P., Caravita, T., Ciccone, G. & Boccadoro, M. (2004) Efficacy of 
low-dose thalidomide and dexamethasone as first salvage regimen in multiple 
myeloma. Hematol J, 5, 318-324. 
Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., 
Gentilini, F., Crippa, C., Galli, M., Nozzoli, C., Ria, R., Marasca, R., Montefusco, V., 
Baldini, L., Elice, F., Callea, V., Pulini, S., Carella, A.M., Zambello, R., Benevolo, 
G., Magarotto, V., Tacchetti, P., Pescosta, N., Cellini, C., Polloni, C., Evangelista, A., 
Caravita, T., Morabito, F., Offidani, M., Tosi, P. & Boccadoro, M. (2011) Aspirin, 
warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma 
treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol, 29, 
986-993. 
Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., 
Ciccone, G., Omede, P., Ambrosini, M.T., Gay, F., Bringhen, S., Musto, P., Foa, R., 
Knight, R., Zeldis, J.B., Boccadoro, M. & Petrucci, M.T. (2007) Melphalan, 
prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from 
the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol, 25, 4459-4465. 
Palumbo, A. & Palladino, C. (2012) Venous and arterial thrombotic risks with thalidomide: 
evidence and practical guidance. Therapeutic Advances in Drug Safety, 3, 255-266. 
Palumbo, A., Rajkumar, S.V., Dimopoulos, M.A., Richardson, P.G., San Miguel, J., 
Barlogie, B., Harousseau, J., Zonder, J.A., Cavo, M., Zangari, M., Attal, M., Belch, 
A., Knop, S., Joshua, D., Sezer, O., Ludwig, H., Vesole, D., Blade, J., Kyle, R., 
Westin, J., Weber, D., Bringhen, S., Niesvizky, R., Waage, A., von Lilienfeld-Toal, 
M., Lonial, S., Morgan, G.J., Orlowski, R.Z., Shimizu, K., Anderson, K.C., 
Boccadoro, M., Durie, B.G., Sonneveld, P. & Hussein, M.A. (2008) Prevention of 
thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 22, 
414-423. 
Parker, K., Mitra, S. & Thachil, J. (2018) Is anticoagulating haemodialysis patients with non-
valvular atrial fibrillation too risky? Br J Haematol, 181, 725-736. 
Rajkumar, S.V. & Blood, E. (2006) Lenalidomide and venous thrombosis in multiple 
myeloma. N Engl J Med, 354, 2079-2080. 
Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. & Greipp, P.R. (2006) Phase III clinical 
trial of thalidomide plus dexamethasone compared with dexamethasone alone in 
newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern 
Cooperative Oncology Group. J Clin Oncol, 24, 431-436. 
Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., Geyer, 
S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R.A. & Witzig, T.E. (2002) Combination 
therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin 
Oncol, 20, 4319-4323. 
Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., 
Zeldenrust, S.R., Kumar, S., Greipp, P.R., Fonseca, R., Lust, J.A., Russell, S.J., Kyle, 
R.A., Witzig, T.E. & Gertz, M.A. (2005) Combination therapy with lenalidomide plus 
dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, 4050-4053. 
Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., 
Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2010) Lenalidomide plus high-
dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial 
therapy for newly diagnosed multiple myeloma: an open-label randomised controlled 
trial. Lancet Oncol, 11, 29-37. 
Raskob, G.E., Buller, H.R. & Segers, A. (2018) Edoxaban for Cancer-Associated Venous 
Thromboembolism. N Engl J Med, 379, 95-96. 
Richardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., Williams, 
S.F., Bensinger, W., Badros, A.Z., Vescio, R., Kenvin, L., Yu, Z., Olesnyckyj, M., 
Zeldis, J., Knight, R. & Anderson, K.C. (2009) Safety and efficacy of single-agent 
lenalidomide in patients with relapsed and refractory multiple myeloma. Blood, 114, 
772-778. 
Romualdi, E. & Ageno, W. (2016) Management of recurrent venous thromboembolism in 
cancer patients. Thromb Res, 140 Suppl 1, S128-131. 
San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., 
Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., 
Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, 
D.L., Liu, K., Cakana, A., van de Velde, H. & Richardson, P.G. (2008) Bortezomib 
plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J 
Med, 359, 906-917. 
Sanfilippo, K.M., Luo, S., Carson, K.R. & Gage, B.F. (2017) Aspirin May be Inadequate 
Thromboprophylaxis in Multiple Myeloma. Blood, 130, 3419-3419. 
Sanfilippo, K.M., Luo, S., Gage, B.F., O'Brian, K. & Carson, K.R. (2014) Venous 
Thromboembolism Is Associated with Increased Mortality in Patients with Multiple 
Myeloma. Blood, 124, 2176-2176. 
Schey, S.A., Fields, P., Bartlett, J.B., Clarke, I.A., Ashan, G., Knight, R.D., Streetly, M. & 
Dalgleish, A.G. (2004) Phase I study of an immunomodulatory thalidomide analog, 
CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol, 22, 3269-3276. 
Schoen, M.W., Luo, S., Gage, B., Carson, K.R. & Sanfilippo, K.M. (2018) Association of 
venous thromboembolism with increased mortality in patients with multiple 
myeloma. Journal of Clinical Oncology, 36, 8051-8051. 
Schulman, S., Zondag, M., Linkins, L., Pasca, S., Cheung, Y.W., de Sancho, M., Gallus, A., 
Lecumberri, R., Molnar, S., Ageno, W., Le Gal, G., Falanga, A., Hulegardh, E., 
Ranta, S., Kamphuisen, P., Debourdeau, P., Rigamonti, V., Ortel, T.L. & Lee, A. 
(2015) Recurrent venous thromboembolism in anticoagulated patients with cancer: 
management and short-term prognosis. J Thromb Haemost, 13, 1010-1018. 
Schutt, P., Ebeling, P., Buttkereit, U., Brandhorst, D., Opalka, B., Hoiczyk, M., Flasshove, 
M., Hense, J., Bojko, P., Metz, K., Moritz, T., Seeber, S. & Nowrousian, M.R. (2005) 
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) 
for previously untreated patients with multiple myeloma. Eur J Haematol, 74, 40-46. 
Snowden, J.A., Ahmedzai, S.H., Ashcroft, J., D'Sa, S., Littlewood, T., Low, E., Lucraft, H., 
Maclean, R., Feyler, S., Pratt, G. & Bird, J.M. (2011) Guidelines for supportive care 
in multiple myeloma 2011. Br J Haematol, 154, 76-103. 
Srkalovic, G., Cameron, M.G., Deitcher, S.R., Kattke-Marchant, K. & Hussein, M.A. (2005) 
Incidence and risk factors of venous thromboembolism (VTD) in patients with 
amyloidosis. International seminars in surgical oncology : ISSO, 2, 17-17. 
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol, A., Hajek, 
R., Rosinol, L., Siegel, D.S., Mihaylov, G.G., Goranova-Marinova, V., Rajnics, P., 
Suvorov, A., Niesvizky, R., Jakubowiak, A.J., San-Miguel, J.F., Ludwig, H., Wang, 
M., Maisnar, V., Minarik, J., Bensinger, W.I., Mateos, M.V., Ben-Yehuda, D., 
Kukreti, V., Zojwalla, N., Tonda, M.E., Yang, X., Xing, B., Moreau, P. & Palumbo, 
A. (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple 
myeloma. N Engl J Med, 372, 142-152. 
Stirling, D., Hannant, W.A. & Ludlam, C.A. (1998) Transcriptional activation of the factor 
VIII gene in liver cell lines by interleukin-6. Thromb Haemost, 79, 74-78. 
Storrar, N.P.F., Mathur, A., Johnson, P.R.E. & Roddie, P.H. (2018) Safety and efficacy of 
apixaban for routine thromboprophylaxis in myeloma patients treated with 
thalidomide- and lenalidomide-containing regimens. Br J Haematol. 
Streetly, M., Hunt, B.J., Parmar, K., Jones, R., Zeldis, J. & Schey, S. (2005) Markers of 
endothelial and haemostatic function in the treatment of relapsed myeloma with the 
immunomodulatory agent Actimid (CC-4047) and their relationship with venous 
thrombosis. Eur J Haematol, 74, 293-296. 
Teasell, R.W., Hsieh, J.T., Aubut, J.A., Eng, J.J., Krassioukov, A. & Tu, L. (2009) Venous 
thromboembolism after spinal cord injury. Arch Phys Med Rehabil, 90, 232-245. 
Thachil, J. (2012) Recurrent venous thromboembolism while on anticoagulant therapy. Blood 
Rev, 26, 175-181. 
Thiagarajan, P., Dannenbring, R., Matsuura, K., Tramontano, A., Gololobov, G. & Paul, S. 
(2000) Monoclonal antibody light chain with prothrombinase activity. Biochemistry, 
39, 6459-6465. 
Tosi, P., Zamagni, E., Cellini, C., Ronconi, S., Patriarca, F., Ballerini, F., Musto, P., Di 
Raimondo, F., Ledda, A., Lauria, F., Masini, L., Gobbi, M., Vacca, A., Ria, R., 
Cangini, D., Tura, S., Baccarani, M. & Cavo, M. (2002) Salvage therapy with 
thalidomide in patients with advanced relapsed/refractory multiple myeloma. 
Haematologica, 87, 408-414. 
Trujillo-Santos, J., Ruiz-Gamietea, A., Luque, J.M., Samperiz, A.L., Garcia-Bragado, F., 
Todoli, J.A. & Monreal, M. (2009) Predicting recurrences or major bleeding in 
women with cancer and venous thromboembolism. Findings from the RIETE 
Registry. Thromb Res, 123 Suppl 2, S10-15. 
van Es, N., Coppens, M., Schulman, S., Middeldorp, S. & Buller, H.R. (2014) Direct oral 
anticoagulants compared with vitamin K antagonists for acute venous 
thromboembolism: evidence from phase 3 trials. Blood, 124, 1968-1975. 
van Giezen, J.J. & Jansen, J.W. (1992) Correlation of in vitro and in vivo decreased 
fibrinolytic activity caused by dexamethasone. Ann N Y Acad Sci, 667, 199-201. 
Weber, D., Rankin, K., Gavino, M., Delasalle, K. & Alexanian, R. (2003) Thalidomide alone 
or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol, 21, 
16-19. 
Weber, D.e.a. (2002) Correlation of thrombotic/embolic events (T/E) with features of 
hypercagulability in previously treated patients beore and after treatment with 
thalidmide (T) or thalidomide-dexamethasone (TD) (abstract). Blood, 100, 787. 
Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., 
Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., 
Olesnyckyj, M., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus 
dexamethasone for relapsed multiple myeloma in North America. N Engl J Med, 357, 
2133-2142. 
Weitz, J.I., Lensing, A.W.A., Prins, M.H., Bauersachs, R., Beyer-Westendorf, J., 
Bounameaux, H., Brighton, T.A., Cohen, A.T., Davidson, B.L., Decousus, H., Freitas, 
M.C.S., Holberg, G., Kakkar, A.K., Haskell, L., van Bellen, B., Pap, A.F., Berkowitz, 
S.D., Verhamme, P., Wells, P.S. & Prandoni, P. (2017) Rivaroxaban or Aspirin for 
Extended Treatment of Venous Thromboembolism. N Engl J Med, 376, 1211-1222. 
Yagci, M., Sucak, G.T. & Haznedar, R. (2003) Fibrinolytic activity in multiple myeloma. Am 
J Hematol, 74, 231-237. 
Yang, F., Hellyer, J.A., Than, C., Ullal, A.J., Kaiser, D.W., Heidenreich, P.A., Hoang, D.D., 
Winkelmayer, W.C., Schmitt, S., Frayne, S.M., Phibbs, C.S. & Turakhia, M.P. (2017) 
Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and 
chronic kidney disease. Heart, 103, 818-826. 
Yasin, Z., Quick, D., Thiagarajan, P., Spoor, D., Caraveo, J. & Palascak, J. (1999) Light-
chain paraproteins with lupus anticoagulant activity. Am J Hematol, 62, 99-102. 
Young, A.M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, 
J.A., Lyman, G.H., Hutchinson, C., MacCallum, P., Kakkar, A., Hobbs, F.D.R., 
Petrou, S., Dale, J., Poole, C.J., Maraveyas, A. & Levine, M. (2018) Comparison of 
an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With 
Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-
D). J Clin Oncol, 36, 2017-2023. 
Zangari, M., Barlogie, B., Anaissie, E., Saghafifar, F., Eddlemon, P., Jacobson, J., Lee, C.K., 
Thertulien, R., Talamo, G., Thomas, T., Van Rhee, F., Fassas, A., Fink, L. & Tricot, 
G. (2004a) Deep vein thrombosis in patients with multiple myeloma treated with 
thalidomide and chemotherapy: effects of prophylactic and therapeutic 
anticoagulation. Br J Haematol, 126, 715-721. 
Zangari, M., Barlogie, B., Lee, C.-K., Tricot, A.E., Fassas, A., Anaissie, E., Hollmig, K., 
Thertulien, R., Talamo, G., van Rhee, F., Stover, J.M., Fink, L. & Tricot, G.J. (2004b) 
Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis 
(DVT). Blood, 104, 4914-4914. 
Zangari, M., Fink, L., Zhan, F. & Tricot, G. (2011) Low venous thromboembolic risk with 
bortezomib in multiple myeloma and potential protective effect with 
thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and 
studies of novel combination regimens. Clin Lymphoma Myeloma Leuk, 11, 228-236. 
Zangari, M., Guerrero, J., Cavallo, F., Prasad, H.K., Esseltine, D. & Fink, L. (2008) 
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory 
multiple myeloma. Haematologica, 93, 953-954. 
Zangari, M., Saghafifar, F., Mehta, P., Barlogie, B., Fink, L. & Tricot, G. (2003) The blood 
coagulation mechanism in multiple myeloma. Semin Thromb Hemost, 29, 275-282. 
Zangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, 
L. & Tricot, G. (2002) Thrombogenic activity of doxorubicin in myeloma patients 
receiving thalidomide: implications for therapy. Blood, 100, 1168-1171. 
Zervas, K., Dimopoulos, M.A., Hatzicharissi, E., Anagnostopoulos, A., Papaioannou, M., 
Mitsouli, C., Panagiotidis, P., Korantzis, J., Tzilianos, M. & Maniatis, A. (2004) 
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal 
doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann 
Oncol, 15, 134-138. 
Zonder, J.A., Durie, B.G.M., McCoy, J., Crowley, J., Zeldis, J.B., Ghannam, L. & Barlogie, 
B. (2005) High Incidence of Thrombotic Events Observed in Patients Receiving 
Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple 
Myeloma (MM) without Aspirin (ASA) Prophylaxis. Blood, 106, 3455-3455. 
 
 
Figure 1: Algorithm for risk stratification and choice of anticoagulants for patients with myeloma. 
LMWH- low molecular weight heparin; DOAC - direct oral anticoagulant 
 
Figure 2 - Management of recurrent thrombosis while on anticoagulant therapy in patients with 
myeloma 
 
LMWH- low molecular weight heparin; DOAC - direct oral anticoagulant 
 
